var title_f28_22_29024="Upper GI anatomy PI";
var content_f28_22_29024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Upper digestive tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 537px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29024=[""].join("\n");
var outline_f28_22_29024=null;
var title_f28_22_29025="Patient information: Dyslexia (The Basics)";
var content_f28_22_29025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/47/38641\">",
"         Patient information: Learning disabilities (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dyslexia (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H192486343\">",
"      <span class=\"h1\">",
"       What is dyslexia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dyslexia is a problem that makes it hard for a child to learn to read. Dyslexia has nothing to do with how smart a child is. Children with dyslexia can be just as smart as or smarter than other children their age. But they have brain differences that affect the way they process written words. They have trouble understanding the connection between letters (or groups of letters) and sounds.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H192486358\">",
"      <span class=\"h1\">",
"       What are the symptoms of dyslexia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is not being able to read as well as other children who are the same age or in the same grade. The signs of dyslexia are different for children of different ages.",
"     </p>",
"     <p>",
"      In preschool, children with dyslexia often have trouble:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Learning nursery rhymes",
"       </li>",
"       <li>",
"        Playing rhyming games",
"       </li>",
"       <li>",
"        Pronouncing words (they can confuse words that sound alike)",
"       </li>",
"       <li>",
"        Learning and remembering the names of letters",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In kindergarten and first grade, children with dyslexia often:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble learning letters",
"       </li>",
"       <li>",
"        Can&rsquo;t read words and have trouble spelling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      During the early school years, children with dyslexia have trouble spelling and reading aloud. They read very slowly, guessing at or sounding out words they do not know, and they make a lot of mistakes. They are not good at naming objects, but they can recognize and point to objects. (For example, they might not be able to name a clock if you point to it and ask what it&rsquo;s called, but they can point to the clock if you ask where it is.) Despite their differences, children with dyslexia are often very smart. They often understand a lot of different words and they are curious and have a good imagination.",
"     </p>",
"     <p>",
"      Because children with dyslexia have trouble reading, they sometimes avoid reading. This makes the problem worse because they fall further behind other kids their age. As they get older, their trouble with reading leads to problems in school. That&rsquo;s why it&rsquo;s so important to get children with dyslexia treated early.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H192486373\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If a doctor, nurse, or teacher thinks that your child might have dyslexia, your child will need an evaluation of his or her reading. This is usually done by an expert in reading or education. It can be arranged through the school system or by your child&rsquo;s doctor or nurse.",
"     </p>",
"     <p>",
"      A doctor, nurse, or other expert might also test your child for other learning problems and for health or emotional problems, such as worrying or feeling sad or depressed. Problems in those areas can affect how well a child can read or learn.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H192486390\">",
"      <span class=\"h1\">",
"       How is dyslexia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dyslexia is treated with &ldquo;special education.&rdquo; This is when a child learns from a teacher with special training.",
"     </p>",
"     <p>",
"      When working with children with dyslexia, special education teachers focus on helping the children learn:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The names and sounds of letters",
"       </li>",
"       <li>",
"        How different words and parts of words look and sound",
"       </li>",
"       <li>",
"        How to break up words into different parts",
"       </li>",
"       <li>",
"        How to put different parts of words together like a puzzle",
"       </li>",
"       <li>",
"        The meanings of many different words",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment can also involve giving children extra time to take tests or do certain tasks.",
"     </p>",
"     <p>",
"      The earlier your child gets tested and treated for dyslexia, the better he or she will do in school in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H192486405\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The most important thing you can do is to spend time reading aloud with your child. There are products on the market that claim to help children with dyslexia, but they have not been proven to work.",
"     </p>",
"     <p>",
"      If your child has trouble in school, try to remember that the problem is not that your child is lazy. Your child&rsquo;s brain has differences that make it hard for him or her to read. This can make it hard to do all sorts of schoolwork. But hopefully with the right treatment, your child can learn to work around his or her differences.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H192486420\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38641?source=see_link\">",
"       Patient information: Learning disabilities (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/22/29025?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87359 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29025=[""].join("\n");
var outline_f28_22_29025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486343\">",
"      What is dyslexia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486358\">",
"      What are the symptoms of dyslexia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486373\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486390\">",
"      How is dyslexia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486405\">",
"      Is there anything I can do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192486420\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38641?source=related_link\">",
"      Patient information: Learning disabilities (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29026="Apoptotic cells immune response";
var content_f28_22_29026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    A possible mechanism explaining how defective clearance of apoptotic cells predisposes to systemic autoimmunity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Keith Elkon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29026=[""].join("\n");
var outline_f28_22_29026=null;
var title_f28_22_29027="Diatrizoate meglumine and diatrizoate sodium: Patient drug information";
var content_f28_22_29027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diatrizoate meglumine and diatrizoate sodium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/15/44278?source=see_link\">",
"     see \"Diatrizoate meglumine and diatrizoate sodium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrografin&reg;;",
"     </li>",
"     <li>",
"      MD-76&reg;R;",
"     </li>",
"     <li>",
"      MD-Gastroview&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diatrizoate meglumine, diatrizoate sodium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given by mouth, as a shot into a vein, or rectally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11626 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29027=[""].join("\n");
var outline_f28_22_29027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158959\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025969\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025968\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025973\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025974\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025976\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025971\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025978\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/15/44278?source=related_link\">",
"      Diatrizoate meglumine and diatrizoate sodium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29028="Latanoprost and timolol: Patient drug information";
var content_f28_22_29028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Latanoprost and timolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/39/23158?source=see_link\">",
"     see \"Latanoprost and timolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9662409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xalacom&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to latanoprost, timolol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an eye infection, eye surgery, or eye injury, start a new bottle of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye color may change with use. This drug may raise the brown pigment. Dark eyelashes and skin around the eye may also happen. These changes may be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Throw away any part not used after 10 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator if not using right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12237 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29028=[""].join("\n");
var outline_f28_22_29028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662409\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023541\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023540\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023545\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023546\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023548\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023543\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023544\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023549\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023550\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/39/23158?source=related_link\">",
"      Latanoprost and timolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29029="Levorphanol: Drug information";
var content_f28_22_29029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levorphanol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/62/20452?source=see_link\">",
"    see \"Levorphanol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: Opiate-naive: 2 mg every 6-8 hours as needed; patients with prior opiate exposure may require higher initial doses; usual dosage range: 2-4 mg every 6-8 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American Pain Society recommends an initial dose of 4 mg for severe pain in adults (APS, 6th ed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain:",
"     </b>",
"     Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration.",
"     <b>",
"      There is no optimal or maximal dose for levorphanol in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11450144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Use with caution; initial dose should be reduced in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F188286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; initial dose should be reduced in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 2 mg,",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F188301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe pain; preoperative sedation/analgesia; management of chronic pain (eg, cancer) requiring opioid therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5978065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, hypotension, bradycardia, peripheral vasodilation, cardiac arrest, shock, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS depression, fatigue, drowsiness, dizziness, nervousness, headache, restlessness, anorexia, malaise, confusion, coma, convulsion, insomnia, amnesia, mental depression, hallucinations, paradoxical CNS stimulation, intracranial pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, dyspepsia, stomach cramps, xerostomia, constipation, abdominal pain, dry mouth, biliary tract spasm, paralytic ileus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Decreased urination, urinary tract spasm, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression, apnea, hypoventilation, cyanosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Histamine release, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levorphanol or any component of the formulation; pregnancy (prolonged use or high doses at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with  hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe liver dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F188279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Neonates born to mothers receiving opioids during pregnancy should be monitored for neonatal withdrawal syndrome and respiratory depression.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levorphanol Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $194.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F188261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levorphanol tartrate is a synthetic opioid agonist that is classified as a morphinan derivative. Opioids interact with stereospecific opioid receptors in various parts of the central nervous system and other tissues. Analgesic potency parallels the affinity for these binding sites. These drugs do not alter the threshold or responsiveness to pain, but the perception of pain.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 10-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 11-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29029/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29029/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinclair JG and Lo GF, &ldquo;The Blockade of Serotonin Uptake and the Meperidine-Monoamine Oxidase Inhibitor Interaction,&rdquo;",
"      <i>",
"       Proc West Pharmacol Soc",
"      </i>",
"      , 1977, 20:373-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29029/abstract-text/19768/pubmed\" id=\"19768\" target=\"_blank\">",
"        19768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9556 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29029=[""].join("\n");
var outline_f28_22_29029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188299\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188284\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188285\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11450144\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188286\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188264\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188248\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188301\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188267\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978065\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188297\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188270\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188252\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299599\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188279\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079698\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188291\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323309\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188261\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188251\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188269\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/62/20452?source=related_link\">",
"      Levorphanol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29030="Basic airway management in children";
var content_f28_22_29030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic airway management in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29030/contributors\">",
"     Pamela Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29030/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29030/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29030/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/22/29030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective airway support is an essential component of successful cardiopulmonary resuscitation. Respiratory insufficiency leading to respiratory arrest typically precedes cardiac arrest for most children. Survival rates between 43 and 82 percent have been reported for children who have been resuscitated from respiratory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, between 4 and 14 percent of children who go on to develop cardiac arrest survive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Basic airway management (including positioning to open the airway and positive pressure ventilation with mouth-to-mouth and bag and mask) will be reviewed here.",
"   </p>",
"   <p>",
"    The following related topics are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced airway management in children (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Basic life support in infants and children (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"       \"Basic life support in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The initial assessment and stabilization of critically ill or injured (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"       \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"       \"Guidelines for pediatric advanced life support\"",
"      </a>",
"      ) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Basic airway management in adults (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"       \"Basic airway management in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear, patent airway is a fundamental requirement for effective resuscitation. Anatomic features that make the airways of infants and children more susceptible to obstruction and that must be considered in order to maintain an adequate airway include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The position of the larynx in infants and children is higher and more anterior than in adults. As a result, hyperextension of the neck may worsen obstruction of the upper airway.",
"     </li>",
"     <li>",
"      Because the airways of children are smaller, they are more susceptible to obstruction from edema, mucous plugs, or foreign body.",
"     </li>",
"     <li>",
"      A relatively larger occiput causes passive flexion of the cervical spine, which contributes to a tendency of the posterior pharynx to buckle during resuscitation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. This can be prevented by placing a rolled towel under the child's upper shoulders to keep the chin tilted up.",
"     </li>",
"     <li>",
"      A common cause of airway obstruction in the unresponsive child is the tongue, which is relatively larger compared to the oral cavity in the child than in the adult and can fall back against the hypopharynx in a child with a decreased level of consciousness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONINVASIVE RELIEF OF OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chin-lift",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaw-thrust maneuvers should be performed to open the airway in an unresponsive child before any more invasive airway adjuncts are utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/8\">",
"     8",
"    </a>",
"    ]. These maneuvers place the airway in a neutral position and move the tongue and palatal tissues away from the posterior wall of the pharynx. In-line immobilization of the cervical spine is essential during these procedures if trauma is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The placement of an airway adjunct such as a nasopharyngeal or oral airway may be necessary if neither the chin-lift nor the jaw thrust maneuvers open the airway. The indications and procedures for placement of these airways are discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Airway adjuncts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chin lift",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this technique, the fingers of one hand are placed under the mandible, which is gently lifted upward to move the chin anteriorly. The thumb of the same hand lightly depresses the lower lip to open the mouth. The thumb may also be placed behind the lower incisors to gently lift the chin so that the lower central incisors are anterior to the maxillary central incisors. One hand may be placed on the child's forehead to gently tilt the head into a neutral position if there is no suspicion of neck injury (",
"    <a class=\"graphic graphic_figure graphicRef61533 \" href=\"UTD.htm?13/18/13600\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70710 \" href=\"UTD.htm?38/23/39282\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the chin lift procedure, care must be taken to avoid closing the mouth, pushing on the soft tissues under the chin, or hyperextending the neck (",
"    <a class=\"graphic graphic_figure graphicRef73382 \" href=\"UTD.htm?30/41/31391\">",
"     figure 2",
"    </a>",
"    ) since these actions contribute to airway obstruction.",
"   </p>",
"   <p>",
"    The head-tilt-chin-lift maneuver should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children who are suspected of having head or neck injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Jaw thrust",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jaw thrust is the preferred method for opening the airway when trauma is suspected, in which case, cervical spine immobilization should also be maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .) It is also useful when assisted ventilation with a bag-valve-mask is required. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Bag-mask ventilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The jaw thrust maneuver is performed by grasping the angles of the lower jaw with one hand on each side, and moving the mandible forward so that the lower central incisors are anterior to the upper central incisors (",
"    <a class=\"graphic graphic_picture graphicRef51547 \" href=\"UTD.htm?26/29/27103\">",
"     picture 2",
"    </a>",
"    ). With no evidence of cervical spine injury, a slight head tilt may be added when the jaw thrust alone does not restore airway patency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Airway adjuncts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and nasopharyngeal airways may be useful to improve ventilation, particularly when oropharyngeal structures, such as the tongue, are obstructing the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Oral airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oral airway can be used in an unconscious child to lift the tongue and pharyngeal soft tissues off of the posterior pharynx to maintain a patent airway (",
"    <a class=\"graphic graphic_picture graphicRef50230 \" href=\"UTD.htm?2/29/2527\">",
"     picture 3",
"    </a>",
"    ). Direct contact with the tongue and supraglottic structures may stimulate vomiting.",
"   </p>",
"   <p>",
"    An oral airway is optimally used as a bridge to recovery for a patient whose condition is expected to be temporary (such as a child who is post-ictal or recovering from sedation). However, prolonged tolerance of an oral airway usually suggests the need for endotracheal (ET) intubation.",
"   </p>",
"   <p>",
"    Selection of the appropriate size and careful placement are necessary to use this device effectively and safely. To choose the correctly sized oral airway, hold it along the side of the child's face with the flange at the corner of the mouth. The tip of the airway should reach the angle of the mandible (",
"    <a class=\"graphic graphic_picture graphicRef77645 \" href=\"UTD.htm?42/45/43728\">",
"     picture 4",
"    </a>",
"    ). It should be inserted using a tongue depressor to push the tongue to the floor of the mouth to avoid pushing the device into the base of the tongue, thereby obstructing the child's airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nasopharyngeal airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flexible nasal airway bypasses obstruction caused by the tongue and pharyngeal soft tissues with minimal contact with the tongue (",
"    <a class=\"graphic graphic_picture graphicRef69419 \" href=\"UTD.htm?32/48/33551\">",
"     picture 5",
"    </a>",
"    ). It is much less likely to induce emesis than an oral airway and is frequently tolerated by conscious patients.",
"   </p>",
"   <p>",
"    Thus, this device is particularly useful for children with soft tissue upper airway obstruction such as macroglossia or tonsillar hypertrophy, who have normal mentation and respiratory function.",
"   </p>",
"   <p>",
"    The correctly sized nasal airway should extend from the nostril to the tragus of the patient's ear. It should be well-lubricated and gently inserted into the nostril to avoid bleeding from injury to nasal mucosa or adenoidal tissue (",
"    <a class=\"graphic graphic_picture graphicRef79849 \" href=\"UTD.htm?30/4/30786\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the airway has been secured, if the child is not breathing spontaneously, the rescuer should administer two breaths. Each breath should be given over one second [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"     9",
"    </a>",
"    ]. Breaths may be administered using mouth-to-mouth, mouth-to-mouth-and-nose, mouth-to-nose techniques, or with bag-mask ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general principles should be applied no matter which method of ventilation is used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rescue breathing is performed while maintaining the airway with the chin lift or jaw thrust. Only the jaw thrust maneuver should be performed in patients with head or neck trauma.",
"     </li>",
"     <li>",
"      The rescuer administers two slow breaths, delivering each breath over one second. There should be a short pause between breaths to maximize oxygen content and minimize carbon dioxide concentration in the delivered breaths [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The volume that is delivered should be sufficient to make the chest wall rise.",
"     </li>",
"     <li>",
"      Rescue breaths should be provided every six to eight seconds (8 to 10",
"      <span class=\"nowrap\">",
"       breaths/minute)",
"      </span>",
"      for infants (under one year) and children (from one year until the start of puberty) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Rescue breathing, particularly if performed rapidly, may cause gastric distention. This can interfere with further rescue breathing by elevating the diaphragm and compromising lung expansion. Gastric distention can be minimized by giving rescue breaths slowly, which allows an effective tidal volume to be delivered at a lower inspiratory pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/13\">",
"       13",
"      </a>",
"      ]. Cricoid pressure should be applied to compress the esophagus to reduce gastric distension when two rescuers are present; compression of the esophagus also may decrease the risk of regurgitation and aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H31#H31\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Cricoid pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chest compressions should be initiated when there is no pulse or the heart rate is &lt;60 beats per minute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H13#H13\">",
"     \"Basic life support in infants and children\", section on 'Compression to ventilation ratio'",
"    </a>",
"    .) The following compression to ventilation ratios are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For lone rescuers, two ventilations should be delivered during a short pause at the end of every 30th compression.",
"     </li>",
"     <li>",
"      For two rescuers, two ventilations should be delivered at the end of every 15th compression.",
"     </li>",
"     <li>",
"      Once the trachea is intubated, ventilations and compressions can be performed independently. For infants and children, ventilations are given at a rate of 8 to 10 per minute. Compressions are delivered at a rate of 100 per minute without pauses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Coordination of compression and ventilation may be facilitated by counting compressions aloud or using an audio-prompted rate guide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mouth-to-mouth/nose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A barrier should be used for infection control whenever possible during mouth-to mouth, mouth-to-mouth-and-nose, and mouth-to-nose breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mouth-to-mouth breathing (for victims older than one year of age), the rescuer takes a deep breath and places his or her mouth over the victim's mouth to create a tight seal, while pinching the victim's nose closed. For victims younger than one year, the rescuer takes a deep breath and places his or her mouth over the victim's mouth and nose.",
"   </p>",
"   <p>",
"    Mouth-to-nose breathing is a reasonable alternative to mouth-to- mouth-and-nose breathing for infants younger than one year of age. When the mouth-to-nose technique is used, it is necessary for the rescuer to close the infant's mouth during rescue breathing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers who are properly trained can use a bag and mask device to provide ventilation during pediatric resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of ventilation bags are available, flow-inflating (anesthesia) or self-inflating bags. The self-inflating bag is generally preferred for resuscitation. Advantages of this device include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The self-inflating bag reinflates when it is released and does not require a gas source to deliver breaths.",
"     </li>",
"     <li>",
"      The self-inflating bag is easier to use. As compared with the flow-inflating bag, effective bag-mask ventilation can be performed more reliably by healthcare providers with variable levels of expertise using the self-inflating device [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike the flow-inflating bag, the self-inflating ventilation bag requires an oxygen reservoir system to reliably deliver oxygen concentrations above 40 percent. This is because room air is entrained in the system when the bag reinflates. With an oxygen flow rate of 15",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    oxygen concentrations between 95 and 100 percent can be delivered using a 2.5 L bag reservoir system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/17\">",
"     17",
"    </a>",
"    ]. Less oxygen is delivered at higher ventilation rates.",
"   </p>",
"   <p>",
"    Self-inflating ventilation bags typically have a safety pop-off valve that reduces the risk of barotrauma by limiting peak inspiratory pressures to between 35 and 45 cm H2O. However, higher levels of peak inspiratory pressure may be required to provide adequate tidal volume and oxygenation when airway resistance is high or lung compliance is poor. In this situation, the pop-off valve can usually be disabled [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/18\">",
"     18",
"    </a>",
"    ]. Whenever possible, a manometer should be used to monitor peak inspiratory pressure when the pop-off valve is disabled. Clinicians should be familiar with the type of ventilation bags that are used in their facilities.",
"   </p>",
"   <p>",
"    The ventilation bag should have a minimum volume of 450 to 500 mL, even for newly born full-term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/12,19,20\">",
"     12,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mask",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective bag-mask ventilation requires a mask that fits properly. The correct size is the smallest mask that completely covers the victim's mouth and nose without covering the eyes or overlapping the chin (",
"    <a class=\"graphic graphic_picture graphicRef76143 \" href=\"UTD.htm?22/21/22870\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     E-C clamp technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"E-C clamp technique\" has been described by the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"     9",
"    </a>",
"    ]. Utilizing this method, the rescuer can optimally position the airway to deliver effective breaths, while applying the mask tightly to the victim's face to avoid air leaks (",
"    <a class=\"graphic graphic_picture graphicRef55539 \" href=\"UTD.htm?18/17/18705\">",
"     picture 8",
"    </a>",
"    ). The technique is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positioning of the child's head requires two maneuvers (",
"      <a class=\"graphic graphic_picture graphicRef69636 \" href=\"UTD.htm?1/55/1908\">",
"       picture 9",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The neck is flexed forward on the shoulders, such that the external auditory canal is anterior to the shoulder. This may be accomplished in children by placing a towel or roll under the occiput. In infants, the towel must be placed under the shoulders to achieve this position, because of a prominent occiput.",
"     </li>",
"     <li>",
"      The head is then extended on the neck, such that the nose and mouth are pointing toward the ceiling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mask is placed on the child's face, with the narrowest portion of the mask over the bridge of the nose.",
"     </li>",
"     <li>",
"      The little, ring, and index fingers of one hand are then spread from the angle of the mandible forward along the mandible forming the \"E.\" These fingers lift the jaw, pulling the face into the mask.",
"     </li>",
"     <li>",
"      Finally, the thumb and forefinger of the same hand are placed over the top of the mask in a \"C\" shape to squeeze it onto the face, forming a seal between the mask and the face.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with suspected injury to the cervical spine, positioning must be accomplished without moving the neck. In-line manual stabilization must be maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link&amp;anchor=H9#H9\">",
"     \"Pediatric cervical spine immobilization\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breaths are provided by using the other hand to compress the bag until the chest visibly rises. The rescuer should use only the force and tidal volume required to make the chest rise.",
"   </p>",
"   <p>",
"    For some patients, two rescuers may be required to provide effective ventilation (",
"    <a class=\"graphic graphic_picture graphicRef72516 \" href=\"UTD.htm?20/39/21105\">",
"     picture 10",
"    </a>",
"    ). In this situation, one rescuer uses both hands (each hand in the \"E-C\" configuration on either side of the face) to maintain the airway and hold the mask, while another rescuer compresses the ventilation bag. The effectiveness of two-person, bag-mask ventilation was demonstrated in a prospective observational study in which greater peak pressures and mean tidal volumes per weight were generated in manikin models with two-person, as compared with one-person, bag-mask ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29030/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MONITORING ADEQUACY OF VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest motion should be constantly monitored as an indicator of the adequacy of ventilations. It must be assumed that if there is no chest motion during CPR, there is no ventilation. Possible reasons for impaired ventilation in a child without an artificial airway include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A foreign body in the airway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venting of a pop-off valve on the ventilation bag.",
"     </li>",
"     <li>",
"      Inadequate pressure of ventilation.",
"     </li>",
"     <li>",
"      Profound abdominal distension elevating the diaphragm and compromising lung expansion; placement of a nasogastric or orogastric tube can help to prevent this complication.",
"     </li>",
"     <li>",
"      Bilateral pneumothoraces.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory insufficiency leading to respiratory arrest typically precedes cardiac arrest for most children. Patients are much more likely to be successfully resuscitated from respiratory arrest as compared with cardiac arrest.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Features of the pediatric airway make the airways of infants and children more susceptible to obstruction and must be considered in order to maintain an adequate airway. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maneuvers to relieve airway obstruction include chin lift and jaw thrust (",
"      <a class=\"graphic graphic_figure graphicRef61533 \" href=\"UTD.htm?13/18/13600\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53277 \" href=\"UTD.htm?42/28/43470\">",
"       figure 3",
"      </a>",
"      ). Chin lift should",
"      <strong>",
"       not",
"      </strong>",
"      be used for patients with suspected cervical spine injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Noninvasive relief of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral and nasopharyngeal airways may be useful to improve ventilation, particularly when oropharyngeal structures, such as the tongue, are obstructing the airway (",
"      <a class=\"graphic graphic_picture graphicRef77645 \" href=\"UTD.htm?42/45/43728\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62820 \" href=\"UTD.htm?14/26/14754\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69419 \" href=\"UTD.htm?32/48/33551\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79849 \" href=\"UTD.htm?30/4/30786\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Airway adjuncts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilations should be delivered with sufficient pressure and volume to see the chest wall rise. Hyperventilation and gastric extension can be minimized by delivering ventilations slowly (over one second) and with only enough force and tidal volume required to make the chest wall visibly rise. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The E-C clamp technique is a useful method for bag-mask ventilation (",
"      <a class=\"graphic graphic_picture graphicRef55539 \" href=\"UTD.htm?18/17/18705\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bag-mask ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poor chest wall movement suggests inadequate ventilation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring adequacy of ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/1\">",
"      L&oacute;pez-Herce J, Garc&iacute;a C, Dom&iacute;nguez P, et al. Outcome of out-of-hospital cardiorespiratory arrest in children. Pediatr Emerg Care 2005; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/2\">",
"      Schindler MB, Bohn D, Cox PN, et al. Outcome of out-of-hospital cardiac or respiratory arrest in children. N Engl J Med 1996; 335:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/3\">",
"      Young KD, Gausche-Hill M, McClung CD, Lewis RJ. A prospective, population-based study of the epidemiology and outcome of out-of-hospital pediatric cardiopulmonary arrest. Pediatrics 2004; 114:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/4\">",
"      Herlitz J, Engdahl J, Svensson L, et al. Characteristics and outcome among children suffering from out of hospital cardiac arrest in Sweden. Resuscitation 2005; 64:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/5\">",
"      Todres ID. Pediatric airway control and ventilation. Ann Emerg Med 1993; 22:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/6\">",
"      Goetting MG. Mastering pediatric cardiopulmonary resuscitation. Pediatr Clin North Am 1994; 41:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/7\">",
"      RUBEN HM, ELAM JO, RUBEN AM, GREENE DG. Investigation of upper airway problems in resuscitation. 1. Studies of pharyngeal x-rays and performance by laymen. Anesthesiology 1961; 22:271.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig S, Lavelle JM. Resuscitation - Pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/9\">",
"      Berg MD, Schexnayder SM, Chameides L, et al. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S862.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons, Committee on Trauma. Advanced trauma life support, 6th ed, American College of Surgeons, Chicago 1997.",
"    </li>",
"    <li>",
"     King BR, King C, Coates WC. Critical procedures. In: APLS: The Pediatric Emergency Medicine Resource, 4th, Gausche-Hill M, Fuchs S, Yamamoto L.  (Eds), Jones and Bartlett, Sudbury 2004. p.692.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/12\">",
"      Terndrup TE, Kanter RK, Cherry RA. A comparison of infant ventilation methods performed by prehospital personnel. Ann Emerg Med 1989; 18:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/13\">",
"      Melker RJ. Asynchronous and other alternative methods of ventilation during CPR. Ann Emerg Med 1984; 13:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/14\">",
"      Berg RA, Sanders AB, Milander M, et al. Efficacy of audio-prompted rate guidance in improving resuscitator performance of cardiopulmonary resuscitation on children. Acad Emerg Med 1994; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/15\">",
"      Kanter RK. Evaluation of mask-bag ventilation in resuscitation of infants. Am J Dis Child 1987; 141:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/16\">",
"      Mondolfi AA, Grenier BM, Thompson JE, Bachur RG. Comparison of self-inflating bags with anesthesia bags for bag-mask ventilation in the pediatric emergency department. Pediatr Emerg Care 1997; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/17\">",
"      Campbell TP, Stewart RD, Kaplan RM, et al. Oxygen enrichment of bag-valve-mask units during positive-pressure ventilation: a comparison of various techniques. Ann Emerg Med 1988; 17:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/18\">",
"      Hirschman AM, Kravath RE. Venting vs ventilating. A danger of manual resuscitation bags. Chest 1982; 82:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/19\">",
"      Field D, Milner AD, Hopkin IE. Efficiency of manual resuscitators at birth. Arch Dis Child 1986; 61:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/20\">",
"      Milner AD. Resuscitation at birth. Eur J Pediatr 1998; 157:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29030/abstract/21\">",
"      Davidovic L, LaCovey D, Pitetti RD. Comparison of 1- versus 2-person bag-valve-mask techniques for manikin ventilation of infants and children. Ann Emerg Med 2005; 46:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6383 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-74C7246191-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29030=[""].join("\n");
var outline_f28_22_29030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONINVASIVE RELIEF OF OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chin lift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Jaw thrust",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Airway adjuncts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Oral airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nasopharyngeal airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mouth-to-mouth/nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bag",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mask",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - E-C clamp technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MONITORING ADEQUACY OF VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6383\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6383|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/18/13600\" title=\"figure 1\">",
"      Head tilt chin lift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/41/31391\" title=\"figure 2\">",
"      Airway in hyperextension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/28/43470\" title=\"figure 3\">",
"      Jaw thrust",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/26/14754\" title=\"figure 4\">",
"      Oropharyn airway insert",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6383|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/23/39282\" title=\"picture 1\">",
"      Head-tilt chin-lift maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/29/27103\" title=\"picture 2\">",
"      Jaw thrust maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/29/2527\" title=\"picture 3\">",
"      Oropharyngeal airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/45/43728\" title=\"picture 4\">",
"      Orophyarngeal airway sizing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/48/33551\" title=\"picture 5\">",
"      Nasopharyngeal airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30786\" title=\"picture 6\">",
"      Nasopharyngeal airway insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/21/22870\" title=\"picture 7\">",
"      Mask size pediatric",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/17/18705\" title=\"picture 8\">",
"      E-C technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/55/1908\" title=\"picture 9\">",
"      Pediatric position for ventilation and intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/39/21105\" title=\"picture 10\">",
"      Two rescuer bag pediatric",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29031="Treatment of hypertension in patients with heart failure";
var content_f28_22_29031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypertension in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29031/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29031/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29031/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29031/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29031/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29031/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/22/29031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a risk factor for the development of heart failure (HF), both because hypertension increases cardiac work, which leads to the development of left ventricular hypertrophy, and because hypertension is a risk factor for the development of coronary heart disease. The relative risk of HF among patients with hypertension, compared with that of the general population, was estimated to be 1.4 in an analysis from the First National Health and Nutrition Examination Survey [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with HF may present with hypertension. In contrast to the pattern seen in the general population, in which prognosis is poorer for hypertensive than for normotensive individuals, higher blood pressure prior to treatment is a predictor of better survival in these patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. It is likely that this correlation is a consequence of the fact that more severe cardiac dysfunction causes a decline in systemic blood pressure, making low blood pressure a marker for more advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/4\">",
"     4",
"    </a>",
"    ]. This observation makes it difficult to study the benefits of antihypertensive therapy in this population.",
"   </p>",
"   <p>",
"    Hypertension imposes an increased hemodynamic load on the failing ventricle in patients with established HF. Thus, small changes in afterload in HF can produce large changes in stroke volume (",
"    <a class=\"graphic graphic_figure graphicRef55742 \" href=\"UTD.htm?38/50/39725\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, a mechanistic argument exists for the treatment of hypertension or even \"normal\" blood pressure in HF to lower systemic vascular resistance. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several classes of drugs, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and aldosterone antagonists, have been shown to prolong survival in patients with HF, independent of their hemodynamic effects.",
"   </p>",
"   <p>",
"    Treatment of hypertension in patients with HF must take into account the type of heart failure that is present: systolic dysfunction, in which impaired cardiac contractility is the primary abnormality; or diastolic dysfunction, in which there is a limitation to diastolic filling and therefore in forward output due to increased ventricular stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Hypertension and ischemic heart disease are the major causes of diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between these two, not mutually exclusive, types of heart failure can be made by measurement of the left ventricular ejection fraction (LVEF). The LVEF is normal or increased with pure diastolic dysfunction, since contractility is not impaired. Establishing the type of HF that is present is important because it determines which antihypertensive agents should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of antihypertensive therapy in the setting of systolic dysfunction are to reduce both preload (to diminish congestive symptoms) and afterload (to improve cardiac contractility). As a result, the preferred antihypertensive agents are diuretics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , ACE inhibitors and beta blockers, all of which improve survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors are one of the primary therapies for HF. When given to patients with mild to advanced HF (many of whom are not hypertensive), they increase cardiac output, diminish congestive symptoms (mostly via venodilation), reduce the rate of progressive cardiac dysfunction, and decrease cardiovascular mortality at one to four years (",
"    <a class=\"graphic graphic_figure graphicRef70015 \" href=\"UTD.htm?10/28/10701\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. An ACE inhibitor is more effective in diminishing mortality than the vasodilator combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACE inhibitors are also beneficial in patients with asymptomatic left ventricular dysfunction. In this setting, treated patients have better preservation of cardiac function, as manifested by less ventricular dilatation and a lower incidence of progression to overt heart failure; late mortality may also be reduced (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors have an additional advantage in hypertensive patients with left ventricular hypertrophy, promoting more regression of left ventricular hypertrophy than beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The greater benefit associated with ACE inhibitors in maintaining cardiac performance may be related to inhibition of the local cardiac renin-angiotensin system, thereby diminishing the deleterious effects of angiotensin II on myocardial function and ventricular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these beneficial cardiovascular effects, ACE inhibitors generally do not improve the glomerular filtration rate in HF. To the contrary, there is a rise (usually modest) in the plasma creatinine concentration in approximately 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/14\">",
"     14",
"    </a>",
"    ]. This complication is most likely to occur in patients in whom maintenance of the glomerular filtration rate is dependent upon angiotensin II, such as those on high-dose diuretic therapy. These patients are also at greater risk of first-dose hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=see_link\">",
"     \"Renal effects of ACE inhibitors in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although black patients have a lesser antihypertensive response than whites to ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/15\">",
"     15",
"    </a>",
"    ], the bulk of evidence supports similar cardiovascular protection in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. As a result, it is generally recommended that blacks be treated the same as whites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H8#H8\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Influence of race'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning ACE inhibitor therapy with low doses (eg, 2.5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    twice daily or 6.25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    three times daily) will reduce the likelihood of hypotension and azotemia. If initial therapy is tolerated, the dose is then gradually increased until side effects occur or maintenance doses are reached (eg, 40 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These relatively high doses are recommended because they were used in the successful trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/17\">",
"     17",
"    </a>",
"    ]; it remains uncertain if lower doses provide the same degree of cardiac protection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent therapy with nonsteroidal antiinflammatory drugs (including 325 of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    per day) can reduce the hemodynamic improvement associated with ACE inhibitors in advanced heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/18\">",
"     18",
"    </a>",
"    ]. The vasoconstriction induced by angiotensin II in HF is partially ameliorated by the release of vasodilator prostaglandins; blocking this response may minimize the degree to which the vascular resistance falls after the administration of an ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II receptor blocking drugs (ARBs) are most often used in patients who are intolerant of ACE inhibitors or in preference to an ACE inhibitor in patients who are already taking an ARB for some other reason. There is no reason to combine an ARB with an ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain beta blockers, in particular,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , have been shown to improve overall and event-free survival in patients with mild to advanced HF (",
"    <a class=\"graphic graphic_figure graphicRef62633 graphicRef75356 \" href=\"UTD.htm?29/30/30190\">",
"     figure 5A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The improvement in survival appears to be additive to that induced by ACE inhibitors (",
"    <a class=\"graphic graphic_figure graphicRef70054 \" href=\"UTD.htm?28/9/28829\">",
"     figure 6",
"    </a>",
"    ). Beta blocker therapy should be considered, independent of hypertension, in patients with New York Heart Association class II, III, or IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) who have been stabilized on an ACE inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .) Beta blockers can also provide anginal relief in patients with ischemic heart disease and rate control in patients with atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the safe initiation of therapy have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/22\">",
"     22",
"    </a>",
"    ]. Therapy must be begun in",
"    <strong>",
"     very low doses",
"    </strong>",
"    and the dose doubled at weekly intervals until the target dose is reached or symptoms become limiting. Initial and target doses are: for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , 3.125 mg BID and 25 to 50 mg BID (the higher dose being used in subjects over 85 kg); for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , 6.25 mg BID and 50 to 75 mg BID, and for extended-release metoprolol, 12.5 or 25 mg daily and titrated up to 200",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    and for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , 1.25 mg once daily and 5 to 10 mg once daily.",
"   </p>",
"   <p>",
"    Dose increases are generally made at two week intervals. Even lower starting doses should be given to patients with recent decompensation of a systolic pressure below 85 mmHg. Every effort should be made to achieve the target dose since the improvement appears to be dose-dependent.",
"   </p>",
"   <p>",
"    The patient should weigh himself or herself daily and call the physician if there has been a 1 to 1.5 kg weight gain. Weight gain alone may be treated with diuretics, but resistant edema or more severe decompensation may require the cessation (possibly transient) of the beta blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic therapy for signs of fluid overload (pulmonary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral edema) is usually initiated with a loop diuretic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ). The fall in intracardiac filling pressure that results from diuretic-induced fluid removal with diuretics will tend to lower the cardiac output and blood pressure. The fall in output is usually well tolerated; however, an otherwise unexplained rise in BUN should be viewed as a sign of a potentially important reduction in tissue perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to fluid removal with loop diuretics, aldosterone antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    at a dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    have been shown to improve survival in patients with advanced HF (",
"    <a class=\"graphic graphic_figure graphicRef76232 \" href=\"UTD.htm?31/14/31981\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/23\">",
"     23",
"    </a>",
"    ] or in patients with a recent myocardial infarction and left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/24\">",
"     24",
"    </a>",
"    ]. They may also prevent excess arrhythmic mortality in patients with mild to moderate HF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/25\">",
"     25",
"    </a>",
"    ]. There is evidence for at least two mechanisms of benefit: an elevation in the serum potassium concentration; and prevention of the toxic effect of hyperaldosteronism on the heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antihypertensive drugs have been evaluated in the treatment of HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      was found to be particularly effective in blacks with HF who were already being treated with standard therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/26\">",
"       26",
"      </a>",
"      ]. However, it requires multiple daily doses and may produce more side effects and is less effective than an ACE inhibitor (",
"      <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some initial studies suggested a possible deleterious effect of calcium channel blockers in patients with HF, while later trials with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      showed no mortality benefit (",
"      <a class=\"graphic graphic_figure graphicRef78557 \" href=\"UTD.htm?13/24/13709\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Thus, there is no direct role for these drugs in the management of HF. However, amlodipine and felodipine appear to be safe and well tolerated and can be used for the treatment of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=see_link\">",
"       \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIASTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of diastolic dysfunction is uncertain. The role of renin-angiotensin system blockers is less clear in patients with diastolic dysfunction. The reduction in afterload can induce hypotension in some cases; however, these drugs can also lead to symptomatic improvement and a reduction in left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/29\">",
"     29",
"    </a>",
"    ]. Beta blockers, ARBs, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    may be beneficial in this setting.",
"   </p>",
"   <p>",
"    Diuretics or venodilators such as nitrates and dihydropyridine calcium channel blockers should be used with caution in diastolic dysfunction. The patient who has left ventricular diastolic dysfunction with a small, stiff left ventricular chamber is particularly susceptible to excessive preload reduction, which can lead sequentially to underfilling of the left ventricle, a fall in cardiac output, and hypotension. In patients with severe LVH due to hypertension or a hypertrophic cardiomyopathy, excessive preload reduction can also create a subaortic outflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Regression of LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is frequently present in patients with diastolic dysfunction. Regression of LVH is an important therapeutic goal, since diastolic function may be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/30\">",
"     30",
"    </a>",
"    ]. A meta-analysis published in 2003 attempted to evaluate the relative efficacy of different antihypertensive drugs for their ability to reverse LVH in patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/12\">",
"     12",
"    </a>",
"    ]. Eighty trials that included 146 and 17 active treatment and placebo arms, respectively, were evaluated. After statistical adjustments for length of therapy and degree of blood pressure lowering, the relative reductions in left ventricular mass index were (",
"    <a class=\"graphic graphic_figure graphicRef82558 \" href=\"UTD.htm?42/42/43693\">",
"     figure 9",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) - 13 percent",
"     </li>",
"     <li>",
"      Calcium channel blockers - 11 percent",
"     </li>",
"     <li>",
"      ACE inhibitors - 10 percent",
"     </li>",
"     <li>",
"      Diuretics - 8 percent",
"     </li>",
"     <li>",
"      Beta blockers - 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ARBs, calcium channel blockers, and ACE inhibitors produced significantly more regression than beta blockers. The clinical significance of this difference is uncertain since there is as yet no evidence that more rapid regression of LVH is associated with improved long-term clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive therapy in patients with HF is supported by the mechanistic rationale that reducing hemodynamic load is beneficial in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most patients with systolic HF are treated with ACE inhibitors or ARBs, beta blockers, and, in selected patients, an aldosterone antagonist. These agents have favorable effects on survival in HF that are independent of their effects on blood pressure. Thus, even if no blood pressure response is seen when these agents are used in a patient with HF, they should not be discontinued, but should be supplemented. As described above, appropriate agents may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal target blood pressure for patients with HF has not been defined. For patients with HF due to systolic dysfunction, many experts consider the goal of therapy to be the lowest blood pressure that is not associated with symptoms of hypotension or evidence of hypoperfusion (eg, worsening prerenal azotemia). In some patients with severe HF, this may be a blood pressure as low as 90 mmHg systolic, but in patients with hypertension and HF, such a low goal is not typically achievable.",
"   </p>",
"   <p>",
"    Some guidance is available in data from clinical trials in HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EPHESUS trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      versus placebo, in which most patients were treated with a beta blocker and either an ACE inhibitor or an ARB, those also treated with eplerenone had a mean blood pressure of",
"      <span class=\"nowrap\">",
"       124/75",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CHARM-Added trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      versus placebo, in which most patients were treated with a beta blocker and an ACE inhibitor but not an aldosterone antagonist, those also treated with candesartan had a mean blood pressure below",
"      <span class=\"nowrap\">",
"       125/75",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29031/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with HF due to diastolic dysfunction, blood pressure reduction is further complicated by the risk of excessive preload or afterload reduction in a patient with a small, stiff ventricle and a relatively invariant left ventricular ejection volume, resulting in a fall in cardiac output. In this setting the achievable blood pressure varies widely from patient to patient.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/1\">",
"      He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/2\">",
"      Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/3\">",
"      Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003; 89:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/4\">",
"      Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/5\">",
"      Mant J, Al-Mohammad A, Swain S, et al. Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 2011; 155:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/6\">",
"      Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993; 22:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/7\">",
"      Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992; 117:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/8\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/9\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/10\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/11\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/12\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/13\">",
"      Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/14\">",
"      Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/15\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/16\">",
"      Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/17\">",
"      Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/18\">",
"      Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/19\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/20\">",
"      The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/21\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/22\">",
"      Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/23\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/24\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/25\">",
"      Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/26\">",
"      Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/27\">",
"      Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/28\">",
"      Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/29\">",
"      Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/30\">",
"      Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29031/abstract/31\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3838 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29031=[""].join("\n");
var outline_f28_22_29031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIASTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Regression of LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3838|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/50/39725\" title=\"figure 1\">",
"      Afterload and cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10701\" title=\"figure 2\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/46/20205\" title=\"figure 3\">",
"      ACEI vs hydralazine in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 4\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/47/12029\" title=\"figure 5A\">",
"      Carvedilol in HF I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/63/26621\" title=\"figure 5B\">",
"      Carvedilol in HF II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/9/28829\" title=\"figure 6\">",
"      Mortality HF ACE beta block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/14/31981\" title=\"figure 7\">",
"      Spironolactone in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/24/13709\" title=\"figure 8\">",
"      Felodipine in HF V HeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/42/43693\" title=\"figure 9\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=related_link\">",
"      Renal effects of ACE inhibitors in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29032="All trans retinoic acid (tretinoin): Drug information";
var content_f28_22_29032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   All trans retinoic acid (tretinoin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/51/30517?source=see_link\">",
"    see \"All trans retinoic acid (tretinoin): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/26/28071?source=see_link\">",
"    see \"All trans retinoic acid (tretinoin): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vesanoid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Retinoic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Remission induction (in combination with an anthracycline &plusmn; cytarabine; unlabeled use):",
"     </i>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses until complete remission or 90 days (Powell, 2010) or until complete hematologic remission (Ades, 2008; Sanz, 2008; Sanz, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Remission induction (in combination with arsenic trioxide; unlabeled use):",
"     </i>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses until &lt;5% blasts in marrow and no abnormal promyelocytes or up to 85 days (Estey, 2006; Ravandi, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Consolidation therapy (unlabeled use):",
"     </i>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses for 15 days each month for 3 months (in combination with chemotherapy) (Lo-Coco, 2010; Sanz 2010)",
"     <b>",
"      or",
"     </b>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 14 days every 4 weeks for 7 cycles (in combination with arsenic trioxide) (Ravandi, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance therapy, intermediate- and high-risk patients (unlabeled use):",
"     </i>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses for 15 days every 3 months for 2 years (Sanz, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F230440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/26/28071?source=see_link\">",
"      see \"All trans retinoic acid (tretinoin): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Remission induction:",
"     </i>",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses until documentation of complete remission (CR); discontinue 30 days after CR or after 90 days of treatment, whichever occurs first",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Remission induction (in combination with an anthracycline; unlabeled use):",
"     </i>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses until complete remission or 90 days (Ortega, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Consolidation therapy, intermediate- and high-risk patients (unlabeled use):",
"     </i>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses for 15 days each month for 3 months (Ortega, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance therapy, intermediate- and high-risk patients (unlabeled use):",
"     </i>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 equally divided doses for 15 days every 3 months for 2 years (Ortega, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16336699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16336700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F8771485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     APL differentiation syndrome: Initiate dexamethasone 10 mg I.V. every 12 hours for 3-5 days; consider interrupting tretinoin until resolution of hypoxia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Liver function tests &gt;5 times the upper limit of normal: Consider temporarily withholding treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally with a meal; do not crush capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Although the manufacturer does not recommend the use of the capsule contents to extemporaneously prepare tretinoin suspension, there are limited case reports of use in patients who are unable to swallow the capsules whole. In a patient with a nasogastric (NG) tube, tretinoin capsules were cut open, with partial aspiration of the contents into a glass syringe, the residual capsule contents were mixed with soy bean oil and aspirated into the same syringe and administered (Shaw, 1995). Tretinoin capsules have also been mixed with sterile water (~20 mL) and heated in a water bath (37&deg;C) to melt the capsules and create an oily suspension for NG tube administration (Bargetzi, 1996). Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (Kueh, 1999). Low plasma concentrations have been reported when tretinoin has been administered through a feeding tube, although patient-specific impaired absorption or a lack of excipient (eg, soybean oil) may have been a contributing factor (Takitani, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent - use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of remission in patients with acute promyelocytic leukemia (APL), French American British (FAB) classification M3 (including the M3 variant) characterized by t(15;17) translocation and/or PML/RAR&alpha; gene presence",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8771106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Post consolidation and maintenance therapy in APL; combination therapy (with arsenic trioxide) for remission induction in APL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16254058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin may be confused with ISOtretinoin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin (which is also called all-",
"       <i>",
"        trans",
"       </i>",
"       retinoic acid, or ATRA) may be confused with isotretinoin; while both products may have uses in cancer treatment, they are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most patients will experience drug-related toxicity, especially headache, fever, weakness and fatigue. These are seldom permanent or irreversible and do not typically require therapy interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (52%), chest discomfort (32%), edema (29%), arrhythmias (23%), flushing (23%), hypotension (14%), hypertension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (86%), fever (83%), malaise (66%), pain (37%), dizziness (20%), anxiety (17%), depression (14%), insomnia (14%), confusion (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin/mucous membrane dryness (77%), rash (54%), pruritus (20%), alopecia (14%), skin changes (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia and/or hypertriglyceridemia (&le;60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (57%), GI hemorrhage (34%), abdominal pain (31%), mucositis (26%), diarrhea (23%), weight gain (23%), anorexia (17%), constipation (17%), weight loss (17%), dyspepsia (14%), abdominal distention (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (60%), leukocytosis (40%), disseminated intravascular coagulation (DIC) (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (50% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (77%), paresthesia (17%), myalgia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Ocular disorder (17%), visual disturbances (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache/ear fullness (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal insufficiency (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract disorders (63%), dyspnea (60%), respiratory insufficiency (26%), pleural effusion (20%), expiratory wheezing (14%), pneumonia (14%), rales (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Shivering (63%), infections (58%), retinoic acid-acute promyelocytic leukemia syndrome differentiation syndrome (&le;25%), diaphoresis (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cerebral hemorrhage (9%), cardiac failure (6%), facial edema (6%), pallor (6%), cardiac arrest (3%), cardiomyopathy (3%), heart enlarged (3%), heart murmur (3%), ischemia (3%), MI (3%), myocarditis (3%), pericarditis (3%), stroke (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (9%), intracranial hypertension (9%), hallucination (6%), aphasia (3%), cerebellar edema (3%), CNS depression (3%), coma (3%), dementia (3%), encephalopathy (3%), facial paralysis (3%), forgetfulness (3%), hypotaxia (3%), hypothermia (3%), light reflex absent (3%), seizure (3%), slow speech (3%), somnolence (3%), spinal cord disorder (3%), unconsciousness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cellulitis (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid imbalance (6%), acidosis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Hepatosplenomegaly (9%), ulcer (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (9%), micturition frequency (3%), prostate enlarged (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Ascites (3%), hepatitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flank pain (9%), abnormal gait (3%), asterixis (3%), bone inflammation (3%), dysarthria (3%), hemiplegia (3%), hyporeflexia (3%), leg weakness (3%), tremor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual acuity change (6%), agnosia (3%), visual field deficit (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Acute renal failure (3%), renal tubular necrosis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Lower respiratory tract disorders (9%), pulmonary infiltration (6%), bronchial asthma (3%), larynx edema (3%), pulmonary hypertension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymph disorder (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arterial thrombosis, basophilia, erythema nodosum, genital ulceration, hypercalcemia, hyperhistaminemia, irreversible hearing loss, myositis, organomegaly, pancreatitis, pseudotumor cerebri, renal infarct, Sweet's syndrome, thrombocytosis, vasculitis (skin), venous thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tretinoin, other retinoids, parabens, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; APL differentiation syndrome (DS):",
"     <b>",
"      [U.S. Boxed Warning]: About 25% of patients with APL treated with tretinoin have experienced APL differentiation syndrome (formerly called retinoic-acid-APL [RA-APL] syndrome), which is characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, and pleural or pericardial effusions, edema, and hepatic, renal, and/or multiorgan failure.",
"     </b>",
"     DS usually occurs during the first month of treatment, with some cases reported following the first dose. DS has been observed with or without concomitant leukocytosis and has occasionally been accompanied by impaired myocardial contractility and episodic hypotension; endotracheal intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia, and several patients have expired with multiorgan failure. About one-half of DS cases are severe, which is associated with increased mortality. Management has not been defined, although high-dose steroids given at the first suspicion appear to reduce morbidity and mortality. Regardless of the leukocyte count, at the first signs suggestive of DS, immediately initiate steroid therapy with dexamethasone 10 mg I.V. every 12 hours for 3-5 days; taper off over 2 weeks. Most patients do not require termination of tretinoin therapy during treatment of DS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Venous thrombosis and MI have been reported in patient without risk factors for thrombosis or MI. The risk for thrombosis (arterial and venous) is increased during the first month of treatment. Use with caution with antifibrinolytic agents; thrombotic complications have been reported (rarely) with concomitant use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause headache, malaise, and/or dizziness; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukocytosis:",
"     <b>",
"      [U.S. Boxed Warning]: During treatment, ~40% of patients will develop rapidly evolving leukocytosis.",
"     </b>",
"     A high WBC at diagnosis increases the risk for further leukocytosis and  may be associated with a higher risk of life-threatening complications. If signs and symptoms of the APL-DS syndrome are present together with leukocytosis, initiate treatment with high-dose steroids immediately. Consider adding full-dose chemotherapy (including an anthracycline, if not contraindicated) to the tretinoin therapy on day 1 or 2 for patients presenting with a WBC count of &gt;5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L. Consider adding chemotherapy immediately in patients who presented with a WBC count of &lt;5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, yet the WBC count reaches &ge;6 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 5, or &ge;10 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 10, or &ge;15 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 28.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Up to 60% of patients experienced hypercholesterolemia or hypertriglyceridemia, which were reversible upon completion of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver function test abnormalities: Elevated liver function test results occur in 50% to 60% of patients during treatment. Carefully monitor liver function test results during treatment and give consideration to a temporary withdrawal of tretinoin if test results reach &gt;5 times the upper limit of normal. Most liver function test abnormalities will resolve without interruption of treatment or after therapy completion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, visual disturbances, intracranial noises, or pulsate tinnitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; APL: Tretinoin treatment for APL should be initiated early, discontinue if pending cytogenetic analysis does not confirm APL by t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (caused by translocation of the promyelocytic [PML] gene on chromosome 15 and retinoic acid receptor [RAR] alpha gene on chromosome 17).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required in women of childbearing potential, two reliable forms of contraception should be used during and for 1 month after treatment.",
"     </b>",
"     Microdosed progesterone products (&ldquo;minipill&rdquo;) may provide inadequate pregnancy protection. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment. If possible, initiation of treatment with tretinoin should be delayed until negative pregnancy test result is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchange: Tretinoin (which is also known as all-",
"     <i>",
"      trans",
"     </i>",
"     retinoic acid, or ATRA) and isotretinoin may be confused, while both products may be used in cancer treatment, they are",
"     <b>",
"      not",
"     </b>",
"     interchangeable; verify product prior to dispensing and administration to prevent medication errors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"     Patients with APL are at high risk and can have severe adverse reactions to tretinoin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (minor), CYP2C8 (major), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2E1 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifibrinolytic Agents: Tretinoin (Systemic) may enhance the thrombogenic effect of Antifibrinolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F230422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Absorption of retinoids has been shown to be enhanced when taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease tretinoin levels. Avoid dong quai, St John's wort (may also cause photosensitization). Avoid additional vitamin A supplementation; may lead to vitamin A toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required  in women of childbearing potential, two reliable forms of contraception should be used during and for 1 month after treatment.",
"     </b>",
"     Within 1 week prior to starting therapy, serum or urine pregnancy test (sensitivity 50 mIU/mL) should be collected. If possible, delay therapy until results are available. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment. An increase in fetal resorptions and a decrease in live fetuses were observed in all animal reproduction studies; teratogenic effects have also been observed. Use in humans is limited, however, major fetal abnormalities and spontaneous abortions have been reported with other retinoids. If the clinical condition of a patient presenting with APL during pregnancy warrants immediate treatment, tretinoin use should be avoided in the first trimester; treatment with tretinoin may be considered in the second and third trimester with careful fetal cardiac monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16336698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tretinoin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued prior to treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F230414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The absorption of retinoids (as a class) is enhanced when taken with food. Capsule contains soybean oil.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tretinoin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $2988.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F230402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone marrow cytology to confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (do not withhold treatment initiation for results); monitor CBC with differential, coagulation profile, liver function test results, and triglyceride and cholesterol levels frequently; monitor closely for signs of APL differentiation syndrome (eg, monitor volume status, pulmonary status, temperature, respiration)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Acido (AR);",
"     </li>",
"     <li>",
"      Aberela (NO, SE);",
"     </li>",
"     <li>",
"      Acid A Vit (NL);",
"     </li>",
"     <li>",
"      Acne Free (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Airol (AR, CH, CZ, GR, IT, MY, TW);",
"     </li>",
"     <li>",
"      Alten (MY, SG);",
"     </li>",
"     <li>",
"      Avitcid (FI);",
"     </li>",
"     <li>",
"      Betarretin (PE);",
"     </li>",
"     <li>",
"      Derm A (PH);",
"     </li>",
"     <li>",
"      Effederm (FR);",
"     </li>",
"     <li>",
"      Eudyna (ID, MY, TW);",
"     </li>",
"     <li>",
"      Ilotycin-A (ZA);",
"     </li>",
"     <li>",
"      Locacid (IL);",
"     </li>",
"     <li>",
"      Optimal (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Renova (ZA);",
"     </li>",
"     <li>",
"      Retacnyl (CR, DO, GT, HN, MY, NI, PA, PE, PH, SG, SV, VE);",
"     </li>",
"     <li>",
"      Retavit (IL);",
"     </li>",
"     <li>",
"      Retin A (AT, BB, BM, BS, BZ, CZ, FR, GR, GY, HN, IL, JM, NL, PT, SR, TT);",
"     </li>",
"     <li>",
"      Retin-A (AU, BF, BH, BJ, BR, CH, CI, CN, CO, CY, ET, GB, GH, GM, GN, HK, ID, IE, IR, IT, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, PE, PH, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Retin-a (PK);",
"     </li>",
"     <li>",
"      Retino-A (IN);",
"     </li>",
"     <li>",
"      Retinova (FR, NZ);",
"     </li>",
"     <li>",
"      Retirides (ES);",
"     </li>",
"     <li>",
"      Retrieve Cream (AU, HK);",
"     </li>",
"     <li>",
"      ReviDerm (ID);",
"     </li>",
"     <li>",
"      Stieva-A (AU, CO, KP, MY, PY, TH, UY);",
"     </li>",
"     <li>",
"      Stieva-A forte (MY);",
"     </li>",
"     <li>",
"      T3Actin (MY);",
"     </li>",
"     <li>",
"      Tracne (ID);",
"     </li>",
"     <li>",
"      Trentin (ID);",
"     </li>",
"     <li>",
"      Vesanoid (AR, AT, AU, BE, BR, CH, CN, CZ, FI, FR, GB, IE, IL, IT, JP, KP, MX, NL, NO, PE, PH, PK, PL, PY, TH, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tretinoin appears to bind one or more nuclear receptors and decreases proliferation and induces differentiation of APL cells; initially produces maturation of primitive promyelocytes and repopulates the marrow and peripheral blood with normal hematopoietic cells to achieve complete remission",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%, predominantly to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP; primary metabolite: 4-oxo-all-",
"     <i>",
"      trans",
"     </i>",
"     -retinoic acid; displays autometabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Parent drug: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (63%); feces (30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad&egrave;s L, Sanz MA, Chevret S, et al, &ldquo;Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1078-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/17975017/pubmed\" id=\"17975017\" target=\"_blank\">",
"        17975017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bargetzi MJ, Tichelli A, Gratwohl A, et al, &ldquo;Oral All-Transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Schweiz Med Wochenschr",
"      </i>",
"      , 1996, 126(45):1944-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/8946598/pubmed\" id=\"8946598\" target=\"_blank\">",
"        8946598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen GQ, Shen ZX, Wu F, et al, &ldquo;Pharmacokinetics and Efficacy of Low-Dose All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1996, 10(5):825-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/8656678/pubmed\" id=\"8656678\" target=\"_blank\">",
"        8656678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Estey E, Garcia-Manero G, Ferrajoli A, et al, \"Use of All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(9):3469-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/16373661/pubmed\" id=\"16373661\" target=\"_blank\">",
"        16373661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gregory J, Kim H, Alonzo T, et al, &ldquo;Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1005-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/19743516/pubmed\" id=\"19743516\" target=\"_blank\">",
"        19743516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kueh YK, Liew PP, Ho PC, et al, &ldquo;Sublingual Administration of All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):503-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/10332546/pubmed\" id=\"10332546\" target=\"_blank\">",
"        10332546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurzrock R, Estey E, and Talpaz M, &ldquo;All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid: Tolerance and Biologic Effects in Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(8):1489-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/8336187/pubmed\" id=\"8336187\" target=\"_blank\">",
"        8336187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazzarino M, Regazzi MB, and Corso A, &ldquo;Clinical Relevance of All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid Pharmacokinetics and Its Modulation in Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 1996, 23(5-6):539-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/9031084/pubmed\" id=\"9031084\" target=\"_blank\">",
"        9031084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo Coco F, Avvisati G, Vignetti M, et al, &ldquo;Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(17):3171-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/20644121/pubmed\" id=\"20644121\" target=\"_blank\">",
"        20644121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montesinos P, Bergua JM, Vellenga E, et al, &ldquo;Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Treated with All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid and Anthracycline Chemotherapy: Characteristics, Outcomes, and Prognostic Factors,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(4):775-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/18945964/pubmed\" id=\"18945964\" target=\"_blank\">",
"        18945964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muindi JR, Frankel SR, Huselton C, et al, &ldquo;Clinical Pharmacology of Oral All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid in Patients With Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1992, 52(8):2138-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/1559217/pubmed\" id=\"1559217\" target=\"_blank\">",
"        1559217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JJ, Madero L, Martin G, et al, &ldquo;Treatment With All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7632-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/16234524/pubmed\" id=\"16234524\" target=\"_blank\">",
"        16234524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravandi F, Estey E, Jones D, et al, \"Effective Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(4):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/19075265/pubmed\" id=\"19075265\" target=\"_blank\">",
"        19075265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Grimwade D, Tallman MS, et al, &ldquo;Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(9):1875-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/18812465/pubmed\" id=\"18812465\" target=\"_blank\">",
"        18812465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Martin G, Gonzalez M, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(4):1237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/14576047/pubmed\" id=\"14576047\" target=\"_blank\">",
"        14576047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Montesinos P, Ray&oacute;n C, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(25):5137-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/20393132/pubmed\" id=\"20393132\" target=\"_blank\">",
"        20393132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Montesinos P, Vellenga E, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(8):3130-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/18664623/pubmed\" id=\"18664623\" target=\"_blank\">",
"        18664623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw PJ, Atkins MC, Nath CE, et al, &rdquo;ATRA Administration in the Critically Ill Patient,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1995, 9(7):1288.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/7630206/pubmed\" id=\"7630206\" target=\"_blank\">",
"        7630206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MA, Adamson PC, Balis FM, et al, &ldquo;Phase I and Pharmacokinetic Evaluation of All-",
"      <i>",
"       trans",
"      </i>",
"      -Retinoic Acid in Pediatric Patients With Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1992, 10(11):1666-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/1403049/pubmed\" id=\"1403049\" target=\"_blank\">",
"        1403049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takitani K, Nakao Y, Kosada Y, et al, &ldquo;Low Plasma Levels of All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2004, 76(1):97-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/15114613/pubmed\" id=\"15114613\" target=\"_blank\">",
"        15114613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Testi AM, Biondi A, Lo Coco F, et al, &ldquo;GIMEMA_AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocutic Leukemia (APL) in Children,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(2): 447-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/22/29032/abstract-text/15677559/pubmed\" id=\"15677559\" target=\"_blank\">",
"        15677559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9262 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29032=[""].join("\n");
var outline_f28_22_29032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708896\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230427\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230446\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230429\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230440\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230430\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16336699\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16336700\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771485\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230404\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230389\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230407\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230405\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771106\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254058\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230444\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230410\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230393\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230441\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230398\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230422\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230400\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230413\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230436\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16336698\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230414\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324024\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230402\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230415\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230392\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230409\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/51/30517?source=related_link\">",
"      All trans retinoic acid (tretinoin): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/26/28071?source=related_link\">",
"      All trans retinoic acid (tretinoin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29033="Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown";
var content_f28_22_29033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29033/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/22/29033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been documented that a patient has symptomatic nephrolithiasis, determining the type of stone and the possible presence of either biochemical abnormalities or underlying conditions that predispose to stone formation are essential for guiding therapy to prevent recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE OF STONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be encouraged to retrieve stones they pass or have removed for analysis, although novel computerized tomography (CT) imaging techniques may permit noninvasive discrimination among the main subtypes of urinary calculi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H725865#H725865\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Determination of stone composition'",
"    </a>",
"    .) Analysis of the stone is an essential part of the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients with urolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The other main types include uric acid, struvite (magnesium ammonium phosphate), and cystine stones. The same patient may have a mixed stone (eg, calcium oxalate and uric acid).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Calcium stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stones composed purely or predominantly of calcium oxalate can occur in various disorders. In general, calcium phosphate stones are associated with the same risk factors as calcium oxalate stones (other than hyperoxaluria) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722956\">",
"    <span class=\"h3\">",
"     Biochemical risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of biochemical urinary risk factors are associated with calcium stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalciuria, with or without hypercalcemia.",
"     </li>",
"     <li>",
"      Hyperoxaluria, which may be present in up to 40 percent of male and 15 percent of female stone formers. This is a major risk factor for calcium oxalate stone formation. Marked hyperoxaluria is usually associated with inflammatory bowel disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      malabsorption or primary hyperoxaluria.",
"     </li>",
"     <li>",
"      Hypocitraturia, which can be marked in patients with chronic metabolic acidosis. However, mild hypocitraturia occurs in a significant proportion of stone formers in the absence of clinically apparent acidemia. Citrate is an important inhibitor of calcium oxalate (and calcium phosphate) stone formation.",
"     </li>",
"     <li>",
"      A persistently alkaline urine pH, which can be seen with type I (distal) renal tubular acidosis (even after an acid load). An alkaline urine is associated with calcium phosphate stone formation. [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/5\">",
"       5",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low urine volume, which increases the concentrations of the lithogenic factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722984\">",
"    <span class=\"h3\">",
"     Predisposing conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying conditions that predispose to calcium stone formation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperparathyroidism, which is suspected because of the presence of hypercalcemia that is often mild and intermittent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Affected patients are more prone to have calcium phosphate stones. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medullary sponge kidney; it is estimated that this disorder is present in 12 to 20 percent of calcium stone formers overall, and 20 to 30 percent of stone formers who are women or under the age of 20 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link\">",
"       \"Medullary sponge kidney\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Distal (type 1) renal tubular acidosis, in which the urine pH is persistently high, leads to metabolic acidosis in most patients; there is also a tendency to have medullary nephrocalcinosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Uric acid stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure uric acid stones occur principally due to a persistently acid urine (pH less than 5.5), which promotes uric acid precipitation, as well as in the setting of uric acid overproduction and excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Struvite stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Struvite stones only form in patients with a chronic upper urinary tract infection due to a urease-producing organism such as Proteus or Klebsiella. Affected patients often have multiple magnesium ammonium phosphate crystals in the urine sediment (",
"    <a class=\"graphic graphic_picture graphicRef54594 \" href=\"UTD.htm?34/38/35439\">",
"     picture 1",
"    </a>",
"    ). The stone may grow rapidly over a period of weeks to months and, if not adequately treated, can develop into a staghorn or branched calculus involving the entire renal collecting system (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62009 graphicRef72669 \" href=\"UTD.htm?41/27/42423\">",
"     image 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cystine stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystine stones only develop in patients with cystinuria (an autosomal recessive disorder) due to the poor solubility of cystine in the urine. The diagnosis of cystinuria is made by identification of the pathognomonic hexagonal cystine crystals on urinalysis (which can be seen in the initial urinalysis in about 25 percent of patients; (",
"    <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"     picture 2",
"    </a>",
"    )) and by measurement of a urinary cystine concentration of greater than 250",
"    <span class=\"nowrap\">",
"     mg/liter.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723012\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients presenting with their first stone should undergo a focused history, radiologic imaging, and at least a limited laboratory evaluation. These issues, including the assessment and treatment of patients presenting with suspected nephrolithiasis, are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"     \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is general agreement that a complete metabolic evaluation, in addition to the basic laboratory testing, is indicated in all patients with multiple stones at first presentation, in patients with a strong family history of stones, and in individuals with active stone disease, which is defined as recurrent stone formation, enlargement of existing stones, or the recurrent passage of gravel. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'The complete metabolic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Focused history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of the focused history is to identify stone risk factors, such as a family history of stone disease and certain dietary habits (",
"    <a class=\"graphic graphic_table graphicRef78303 \" href=\"UTD.htm?1/35/1596\">",
"     table 1",
"    </a>",
"    ). These factors are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, adverse dietary habits include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low fluid intake or a high fluid loss (eg, from sweating or gastrointestinal losses), which leads to a lower urine output and, therefore, a higher concentration of lithogenic factors.",
"     </li>",
"     <li>",
"      Higher animal protein diet, which can lead to hypercalciuria, hyperuricosuria, hypocitraturia, and elevated urinary acid excretion (",
"      <a class=\"graphic graphic_figure graphicRef56597 \" href=\"UTD.htm?24/29/25053\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Higher salt diet, which increases urinary calcium excretion.",
"     </li>",
"     <li>",
"      Increased intake of higher oxalate-containing foods, particularly spinach. The exact contribution of dietary oxalate to urinary oxalate is controversial and likely varies considerably from person to person.",
"     </li>",
"     <li>",
"      Lower calcium intake, which acts by increasing the absorption and subsequent excretion of oxalate due to decreased calcium oxalate complex formation within the intestinal lumen [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. The effect on oxalate more than counterbalances the decrease in calcium absorption and excretion.",
"     </li>",
"     <li>",
"      Excessive vitamin C and D supplementation.",
"     </li>",
"     <li>",
"      Excessive sugar (fructose) intake, which may increase calcium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oxalate excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain medications can occasionally crystallize in the urine and lead to stone formation. Examples include,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    &nbsp;, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    . &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723082\">",
"    <span class=\"h2\">",
"     Radiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, an intravenous pyelogram (IVP) was used to establish the diagnosis of nephrolithiasis and to determine the site and degree of obstruction in patients presenting with flank pain. However, a non-contrast-enhanced helical CT scan has proven to be more accurate and, if available, is currently the preferred diagnostic test in such patients. It is important to appreciate that ureteral dilatation without a stone on radiologic examination could represent recent passage of the stone. Radiologic testing of nephrolithiasis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723192\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is disagreement whether a complete metabolic evaluation should be performed after the first stone. Limited data suggest that single stone formers have similar metabolic abnormalities as patients with recurrent nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In addition, there are several studies suggesting that the likelihood of stone formation can be predicted reasonably well from the 24-hour urine values. However, there are data suggesting that a comprehensive medical evaluation is not cost-effective for patients who have only formed one stone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent stones are common. The older literature suggests that, among untreated men with a first calcium stone, the likelihood of forming a second stone is approximately 15 percent at one year, 35 to 40 percent at five years, and 50 percent at 10 years; the values are somewhat lower in women (",
"    <a class=\"graphic graphic_figure graphicRef57270 \" href=\"UTD.htm?14/29/14813\">",
"     figure 2",
"    </a>",
"    ). Subsequent data from the control groups in randomized controlled trials have found recurrence rates of approximately five percent per year for the first five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"     \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three options have been proposed for laboratory evaluation after a first stone: a limited evaluation, a complete metabolic evaluation similar to patients with multiple stones or active stone disease, or a targeted approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723435\">",
"    <span class=\"h3\">",
"     Limited evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the rate of recurrence is variable, some recommend only a limited evaluation after a first stone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/19\">",
"     19",
"    </a>",
"    ]. This approach is based upon the availability of non-operative therapy for most symptomatic stones and avoids unnecessary therapy in those who would not have a recurrence.",
"   </p>",
"   <p>",
"    The limited evaluation should include routine blood chemistries. At least one repeated measurement of serum calcium should be performed in patients whose first value is high-normal since most patients with urolithiasis due to primary hyperparathyroidism, a surgically correctable disease, have values between 10.2 and 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.55 and 2.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/9\">",
"     9",
"    </a>",
"    ]. Other findings that may be important include a low serum phosphorus and a low serum bicarbonate concentration, the latter being suggestive of distal renal tubular acidosis or chronic diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723460\">",
"    <span class=\"h3\">",
"     Complete metabolic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinicians recommend a complete evaluation after the first stone because of the potentially high rate of recurrence (",
"    <a class=\"graphic graphic_figure graphicRef57270 \" href=\"UTD.htm?14/29/14813\">",
"     figure 2",
"    </a>",
"    ), potential morbidity from recurrent stones, and identifying individuals at higher risk for low bone density due to negative calcium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/19\">",
"     19",
"    </a>",
"    ]. This approach should be followed only in individuals willing to make dietary changes or to take medical therapy if warranted by the work-up. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'The complete metabolic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Support for this approach comes from a retrospective analysis of male calcium stone formers that found that the likelihood of relapse on medical therapy was directly correlated with the number of pretreatment symptomatic stones [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence and subsequent growth of multiple stones that were originally too small to detect with available imaging modalities could be one explanation for this observation. Thus, waiting for a patient to declare as a multiple stone former may decrease the response to medical therapy. In addition, some studies suggest that residual stone fragments following either shock wave lithotripsy or percutaneous stone removal may facilitate the formation of new stones, and that selective medical therapy may reduce the chance of recurrent stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=see_link\">",
"     \"Clinical significance of residual stone fragments following stone removal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723485\">",
"    <span class=\"h3\">",
"     Targeted approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third approach is to base the extent of the laboratory evaluation upon an estimation of the risk for new stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/25\">",
"     25",
"    </a>",
"    ]. A complete metabolic evaluation, as described below, would be performed in patients at moderate to high risk for recurrent disease. Patients at high risk for recurrent disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Middle-aged, white males with a family history of stones",
"     </li>",
"     <li>",
"      Patients with chronic diarrheal states",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      malabsorption, pathologic skeletal fractures, osteoporosis, urinary tract infection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gout",
"     </li>",
"     <li>",
"      Patients with stones composed of cystine, uric acid, calcium phosphate, or struvite",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THE COMPLETE METABOLIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic evaluation for nephrolithiasis consists of both blood and urine testing, including at least two 24-hour urine collections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A routine chemistry profile should be obtained, including measurement of serum calcium. Although usually normal, the presence of a low serum bicarbonate concentration raises the possibility of Type I renal tubular acidosis.",
"   </p>",
"   <p>",
"    The serum calcium concentration should be measured looking for hypercalcemia; if high-normal (which we define as above the midpoint of the normal range), the serum calcium should be repeated. A measurement of intact parathyroid hormone is warranted in patients with values in the high-normal range or if the urine calcium is high, since primary hyperparathyroidism is often associated with only intermittent and mild elevations in the serum calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one series of 48 patients with nephrolithiasis and primary hyperparathyroidism, 30 (63 percent) had serum calcium concentrations between 10.2 and 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.55 and 2.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/9\">",
"     9",
"    </a>",
"    ]. The possibility of primary hyperparathyroidism should be particularly suspected in women, since this disorder is more common in women, and in calcium phosphate stone formers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful urinalysis should be performed, since certain findings point toward a specific diagnosis. A urine pH above 7 with phosphate crystals in the urine sediment (",
"    <a class=\"graphic graphic_picture graphicRef54594 \" href=\"UTD.htm?34/38/35439\">",
"     picture 1",
"    </a>",
"    ) is suggestive of calcium phosphate or struvite calculi, while the presence of hexagonal cystine crystals (",
"    <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"     picture 2",
"    </a>",
"    ) is diagnostic of cystinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although uric acid crystals (",
"    <a class=\"graphic graphic_picture graphicRef61827 graphicRef73642 \" href=\"UTD.htm?23/39/24177\">",
"     picture 3A-B",
"    </a>",
"    ) and calcium oxalate crystals (",
"    <a class=\"graphic graphic_picture graphicRef65169 graphicRef67694 \" href=\"UTD.htm?14/28/14788\">",
"     picture 4A-B",
"    </a>",
"    ) may be seen in individuals without stone disease, the specific crystal type in a patient with stone disease is likely to represent the composition of the stone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    crystals (",
"    <a class=\"graphic graphic_picture graphicRef70939 \" href=\"UTD.htm?21/23/21877\">",
"     picture 5",
"    </a>",
"    ) are much more common in patients taking this drug than indinavir lithiasis (20 versus 3 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723806\">",
"    <span class=\"h3\">",
"     Urine calcium-creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although used by some clinicians, we do not recommend using the calcium-creatinine ratio. It is not as accurate as the measurement from a 24-hour urine collection, due in part to substantial variability at different times of the day and depending on the individual's body size (and therefore creatinine generation). (See",
"    <a class=\"local\" href=\"#H17\">",
"     '24-hour urine collections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     24-hour urine collections",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two 24-hour urine collections should be obtained while the patient maintains their usual diet, fluid intake and physical activities given the high variability of the urine values. If there is a substantial discrepancy between two results, a third collection may be required. Urine collections should not be performed if there is evidence of",
"    <span class=\"nowrap\">",
"     renal/ureteral",
"    </span>",
"    obstruction or urinary tract infection from existing calculi. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urine volume, pH, and excretion of calcium, uric acid, citrate, oxalate, sodium, and creatinine (to assess the completeness of the collection) should be measured. In addition, urinary supersaturation should be calculated. Twenty-four hour urine collections may not be helpful in determining the cause of new onset stones in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of definitions for \"normal\" are frequently used for each of the urinary parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium &minus; less than 250 mg (6.25 mmol) per day in women or less than 300 mg (7.5 mmol) per day in men",
"     </li>",
"     <li>",
"      Uric acid &minus; less than 750 mg (4.5 mmol) per day in women or less than 800 mg (4.8 mmol) per day in men",
"     </li>",
"     <li>",
"      Oxalate &minus; less than 45 mg (0.5 mmol) per day in both women and men",
"     </li>",
"     <li>",
"      Citrate &minus; greater than or equal to 320 mg per day in both women and men",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these values are arbitrary and additional data suggest a more linear relation, as the risk continues to decrease as urinary calcium falls below 250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (6.25",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, the concentration of lithogenic factors and the urinary supersaturation, as calculated in an experienced laboratory, are more important than the absolute amounts with respect to stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of creatinine excretion permits assessment of the completeness of the 24-hour collection. The usual rate of urinary creatinine excretion in patients under the age of 50 is 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     &micro;mol/kg)",
"    </span>",
"    of lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     &micro;mol/kg)",
"    </span>",
"    of lean body weight in women. Values substantially below this level suggest an incomplete collection, except for older subjects or malnourished patients with decreased muscle mass. The creatinine value is useful in that it allows comparison of different collections in the same individual.",
"   </p>",
"   <p>",
"    Measurement of sodium excretion is also important. Increased sodium intake can contribute to increased calcium excretion and will affect the response to a thiazide diuretic when prescribed to reduce urine calcium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many laboratories, two or three separate collections are required to obtain all of this information: uric acid is measured in a plain or alkaline solution, calcium and oxalate in hydrochloric or nitric acid, and citrate in an acidified solution. However, some specialized laboratories provide a kit that permits all of the above values to be measured and urinary supersaturation calculated from a single urine collection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Number of collections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of daily variations in dietary intake, which are occasionally large, some have recommended that two to three 24-hour collections be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The validity of this approach was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 75 recurrent idiopathic calcium renal stone formers examined the relative diagnostic utility of one, two, and three urine collections [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/32\">",
"       32",
"      </a>",
"      ]. When compared with one or any combination of two urine collections, three urine collections were significantly associated with the highest yield of identifying a urinary abnormality (",
"      <a class=\"graphic graphic_figure graphicRef72059 \" href=\"UTD.htm?39/21/40285\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similar findings were noted in another report of over 1000 stone formers in whom three 24-hour urine collections were obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/33\">",
"       33",
"      </a>",
"      ]. Differences in urinary biochemical risk factors among the three collections were substantial enough that an important metabolic abnormality would have been missed in many patients if only one sample had been collected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, we recommend that a minimum of two collections be performed as part of the initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Timing of collections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine collections should be obtained in the outpatient setting when the patient is on his or her usual diet; values should",
"    <strong>",
"     not",
"    </strong>",
"    be measured in the hospital. It is common practice to wait at least one to three months after a stone event to obtain the collections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/32\">",
"     32",
"    </a>",
"    ]. At the least, one should wait until the patient has completely recovered from any surgical interventions and make sure that the urine is not infected or the collecting system obstructed. We generally suggest waiting one to two months after the last stone episode, since the patient may have temporarily modified their diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT IF STONE COMPOSITION IS UNKNOWN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a patient with recurrent stone disease (but the type of stone is unknown), it is reasonable to assume that the stone is calcium-based. In this setting, certain disorders associated with calcium nephrolithiasis should be excluded as possible underlying causes. Although one cannot distinguish between calcium oxalate and calcium phosphate stones radiographically, this is less important, because the evaluation will be the same for both stone types.",
"   </p>",
"   <p>",
"    However, if a patient is a recurrent stone former, then it should be made clear to the patient and the treating urologist that a stone",
"    <strong>",
"     must",
"    </strong>",
"    be sent for analysis during the next stone episode. Information about stone composition will then allow for more tailored treatment recommendations.",
"   </p>",
"   <p>",
"    If stone composition is unknown, then treatment recommendations to prevent future stone episodes will be influenced by the 24-hour urine results and the clinical picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723846\">",
"    <span class=\"h2\">",
"     Hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the urine calcium is elevated, then attempts to lower the urine calcium concentration should be instituted (often a thiazide diuretic will be necessary). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hypercalciuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, primary hyperparathyroidism, sarcoidosis, and distal (type 1) renal tubular acidosis should also be considered in the patient with increased urine calcium levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723853\">",
"    <span class=\"h2\">",
"     Hypocitraturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the citrate is low, choosing treatment is a more difficult decision. Supplementing citrate intake (eg, potassium citrate) will increase urinary citrate excretion. However, this will also raise the urinary pH. If the predominant calcium salt is calcium phosphate, which forms more readily in an alkaline urine, supplementation with citrate (which is metabolized to bicarbonate in the body) may, in fact, accelerate the rate of stone formation. In this case, the urine pH may be a useful guide. If the urine pH is 6.5 or higher, the use of citrate supplements should be used with great caution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .) Since citrate inhibits calcium phosphate crystallization, it remains unclear whether the inhibition by citrate or the promotion by increasing pH predominates. Patients with RTA for instance seem to benefit from citrate supplementation despite the potential alkalinization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723861\">",
"    <span class=\"h2\">",
"     Hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hyperoxaluria is present, a low oxalate diet should be tried first. The primary foods to avoid are spinach and nuts. The following site contains the oxalate value for different foods:",
"    <a class=\"external\" href=\"https://regepi.bwh.harvard.edu/health/nutrition.html\">",
"     https://regepi.bwh.harvard.edu/health/nutrition.html",
"    </a>",
"    . Even if the urine calcium is high, increasing dietary calcium or adding an over the counter",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    supplement with meals should be considered in addition to a low oxalate diet if the low oxalate diet alone is insufficient. However, the amount of urinary oxalate that is derived from the diet is quite variable; thus, if a patient adheres to a low oxalate diet and the urine oxalate does not fall, then the oxalate restriction can be removed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Limit dietary oxalate intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723868\">",
"    <span class=\"h2\">",
"     Hyperuricosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hyperuricosuria is present, lifestyle modification with the aim of reducing uric acid production (ie, decreased purine intake and weight loss) should be implemented. However, if the urine pH is 6.0 or higher, the high urine uric acid may not be playing a role, as it will stay in solution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hyperuricosuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729457\">",
"    <span class=\"h2\">",
"     Low urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the urine volume is less than two liters in 24 hours, then patients should increase their fluid intake with the goal of producing at least two liters of urine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/34\">",
"     34",
"    </a>",
"    ]. This will increase the urine flow rate and lower the urine solute concentration, both of which protect against stone formation. Fluid should be ingested throughout the day and at bedtime, and the volume should be increased when sweat losses are greater, such as at higher ambient temperatures and with exercise.",
"   </p>",
"   <p>",
"    The efficacy of increasing fluid intake was illustrated in a controlled trial in which 199 patients with a first calcium stone were randomly assigned to no therapy or recommendation of a high fluid intake to produce two liters of urine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/18\">",
"     18",
"    </a>",
"    ]. At five years, the incidence of new stone formation was significantly lower in the treated patients than in those in the control group (12 versus 27 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Increase fluid intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     No obvious metabolic abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with recurrent calcium stones have no identifiable metabolic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/3,8,29,35\">",
"     3,8,29,35",
"    </a>",
"    ]. However, careful analysis has shown that these patients frequently have more calcium, more oxalate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less citrate in the urine than non-stone formers, although none of the values are clearly \"abnormal\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/3\">",
"     3",
"    </a>",
"    ]. The currently accepted definition of \"abnormal\" for urinary values has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/35\">",
"     35",
"    </a>",
"    ]. If these patients continue to form stones, then the urinary lithogenic factors need to be modified.",
"   </p>",
"   <p>",
"    This was examined in a cross-sectional study of 3350 men and women, of whom 2237 had a history of nephrolithiasis with the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with a 24 hour urine calcium of less than 100 mg, a urinary calcium of 150 to 199 was associated with a relative risk of a stone of 1.52 (95% CI 0.99-2.34); a urinary calcium of 200 to 249 was associated with a relative risk of 1.84 (95% CI1.17-2.9); and a urinary calcium of 250 to 299 was associated with a relative risk of 1.93 (95% CI 1.15-3.24).",
"     </li>",
"     <li>",
"      Compared with a 24-hour urine oxalate of less than 20 mg, a urinary oxalate of 25 to 29 was associated with a relative risk of a stone of 1.59 (95% CI 1.03-2.46), and a urinary oxalate of 30 to 39 was associated with a relative risk of 2.51 (95% CI 1.59-3.96).",
"     </li>",
"     <li>",
"      A urinary citrate of 300 to 399 mg was associated with a decreased risk ratio of stone formation of 0.72 (95% CI 0.4-1.28) compared with a level less than 300. A level of 400 to 499 was associated with a decreased relative risk of 0.63 (95% CI 0.37-1.08) and a level of 500 to 599 was associated with a decreased relative risk of 0.50 (95% CI 0.30-0.83).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study is limited by the fact that the stone composition was unknown in most cases. However, the demographics of the participants suggest that the majority were likely to have had calcium oxalate stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178189\">",
"    <span class=\"h2\">",
"     Use of calculated supersaturations",
"    </span>",
"    &nbsp;&mdash;&nbsp;If supersaturation values can be calculated by the testing laboratory, they provide additional information to help determine how aggressively the urine composition should be modified, and can be used to follow the impact of multiple interventions. As an example, both the 24 hour urine calcium and the supersaturation value for calcium oxalate can be monitored to determine the effect of an intervention such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ; if effective, therapy should result in reductions in both values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H724201\">",
"    <span class=\"h1\">",
"     RADIOLOGIC MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another management issue is whether to monitor a stone former, usually with ultrasonography, abdominal plain films (KUB), or tomography (CT), to determine if new stones have formed or previous stones have increased in size (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57549 \" href=\"UTD.htm?6/41/6804\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/36\">",
"     36",
"    </a>",
"    ]. Monitoring should be performed initially at one year and, if negative, every two to four years thereafter, depending upon the likelihood of recurrence.",
"   </p>",
"   <p>",
"    Several factors should be considered when choosing which modality to use for radiologic monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If stones were previously visible by ultrasonography, then using this modality will minimize cumulative radiation exposure; this is particularly important in women of childbearing age.",
"     </li>",
"     <li>",
"      To allow comparisons of stone burden over time, a modality should be selected that successfully detected previous stones. As an example, ultrasound should not be used for radiologic monitoring if prior stones were only detectable with CT or KUB.",
"     </li>",
"     <li>",
"      CT is the most sensitive test for detecting stones, particularly small stones. However, repeated use of standard CT is associated with the highest cumulative dose of radiation. One study found that 20 percent of patients receive potentially significant radiation doses in the short-term follow-up of an acute stone event [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      By comparison, low dose CT significantly reduces the amount of radiation exposure and continues to be an effective tool in the setting of acute stone evaluation and during follow-up in the urology clinic in patients with urolithiasis. Low dose CT can better assess urolithiasis and associated obstruction than plain abdominal radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29033/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiologic imaging in a patient presenting with acute symptoms of nephrolithiasis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"       \"Patient information: Kidney stones in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22323234\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analysis of the stone is an",
"      <strong>",
"       essential",
"      </strong>",
"      part of the evaluation of patients with established nephrolithiasis. The principal types of kidney stones are calcium (80 percent, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate), uric acid, struvite (magnesium ammonium phosphate), and cystine. Retrieval and analysis of a passed stone will help guide preventive recommendations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Type of stone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients presenting with their first stone should undergo a focused history, radiologic imaging, and at least a limited laboratory evaluation. In patients who have multiple stones at first presentation, a strong family history of stones, or active stone disease (defined as recurrent stone formation, enlargement of existing stones, or the recurrent passage of gravel), a complete metabolic evaluation should be performed in addition to the limited laboratory testing. (See",
"      <a class=\"local\" href=\"#H723012\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'The complete metabolic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The purpose of the focused history is to identify stone risk factors, such as a family history of stone disease and certain dietary habits (",
"      <a class=\"graphic graphic_table graphicRef78303 \" href=\"UTD.htm?1/35/1596\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Focused history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-contrast-enhanced helical computerized tomography is currently the preferred diagnostic test to establish the presence of nephrolithiasis. (See",
"      <a class=\"local\" href=\"#H723082\">",
"       'Radiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three options have been proposed for laboratory evaluation after a first stone: a limited evaluation, a complete metabolic evaluation similar to patients with multiple stones or active stone disease, or a targeted approach. (See",
"      <a class=\"local\" href=\"#H723192\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complete metabolic evaluation for nephrolithiasis consists of both blood and urine testing, including at least two 24-hour urine collections. In each 24-hour urine collection, the urine volume, pH, and excretion of calcium, uric acid, citrate, oxalate, sodium, and creatinine (to assess the completeness of the collection) should be measured. Also, urinary supersaturation should be calculated. Urine collections should not be performed if there is evidence of",
"      <span class=\"nowrap\">",
"       renal/ureteral",
"      </span>",
"      obstruction or urinary tract infection from existing calculi. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'The complete metabolic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a patient with recurrent stone disease in which stone composition is unknown, it is reasonable to assume that the stone is calcium-based. Thus, certain disorders associated with calcium nephrolithiasis should be excluded as possible underlying causes. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment if stone composition is unknown'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If stone composition is unknown, then treatment recommendations to prevent future stone episodes will be influenced by the 24-hour urine results and the clinical picture:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the urine calcium is elevated, then attempts to lower the urine calcium concentration should be instituted (often a thiazide diuretic will be necessary). (See",
"      <a class=\"local\" href=\"#H723846\">",
"       'Hypercalciuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the citrate is low, then supplementing citrate intake (eg, potassium citrate) will increase urinary citrate excretion. If the urine pH is 6.5 or higher, the use of citrate supplements should be used with great caution. (See",
"      <a class=\"local\" href=\"#H723853\">",
"       'Hypocitraturia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If hyperoxaluria is present, a low oxalate diet should be tried first. The following site contains the oxalate value for different foods:",
"      <a class=\"external\" href=\"https://regepi.bwh.harvard.edu/health/nutrition.html\">",
"       https://regepi.bwh.harvard.edu/health/nutrition.html",
"      </a>",
"      . Even if the urine calcium is high, increasing dietary calcium or adding an over the counter calcium supplement with meals should be considered in addition to a low oxalate diet if the low oxalate diet alone is insufficient. (See",
"      <a class=\"local\" href=\"#H723861\">",
"       'Hyperoxaluria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If&nbsp;hyperuricosuria is present, lifestyle modification to reduce uric acid production may be warranted. If dietary measures are insufficient to lower the urinary uric acid,&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      should be considered. (See",
"      <a class=\"local\" href=\"#H723868\">",
"       'Hyperuricosuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the urine volume is less than two liters in 24 hours, then patients should increase their fluid intake with the goal of producing at least two liters of urine per day. (See",
"      <a class=\"local\" href=\"#H729457\">",
"       'Low urine volume'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with stones, radiologic monitoring should be performed initially at one year and, if negative, every two to four years thereafter. (See",
"      <a class=\"local\" href=\"#H724201\">",
"       'Radiologic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/1\">",
"      Kourambas J, Aslan P, Teh CL, et al. Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol 2001; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/2\">",
"      Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/3\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/4\">",
"      Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995; 98:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/5\">",
"      Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/6\">",
"      Curhan GC. Epidemiology of stone disease. Urol Clin North Am 2007; 34:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/7\">",
"      Gault MH, Chafe LL, Morgan JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/8\">",
"      Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/9\">",
"      Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/10\">",
"      Yendt ER, Gagne RJ. Detection of primary hyperparathyroidism, with special reference to its occurrence in hypercalciuric females with \"normal\" or borderline serum calcium. Can Med Assoc J 1968; 98:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/11\">",
"      Yagisawa T, Kobayashi C, Hayashi T, et al. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/12\">",
"      Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/13\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/14\">",
"      von Unruh GE, Voss S, Sauerbruch T, Hesse A. Dependence of oxalate absorption on the daily calcium intake. J Am Soc Nephrol 2004; 15:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/15\">",
"      Strauss AL, Coe FL, Parks JH. Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients. Arch Intern Med 1982; 142:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/16\">",
"      Pak CY. Should patients with single renal stone occurrence undergo diagnostic evaluation? J Urol 1982; 127:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/17\">",
"      Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002; 168:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/18\">",
"      Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/19\">",
"      Parmar MS. Kidney stones. BMJ 2004; 328:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/20\">",
"      Parks JH, Coe FL. An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney Int 1994; 45:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/21\">",
"      Fine JK, Pak CY, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 1995; 153:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/22\">",
"      Carr LK, D'A Honey J, Jewett MA, et al. New stone formation: a comparison of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy. J Urol 1996; 155:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/23\">",
"      Candau C, Saussine C, Lang H, et al. Natural history of residual renal stone fragments after ESWL. Eur Urol 2000; 37:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/24\">",
"      Kang DE, Maloney MM, Haleblian GE, et al. Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. J Urol 2007; 177:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/25\">",
"      Preminger GM. The metabolic evaluation of patients with recurrent nephrolithiasis: a review of comprehensive and simplified approaches. J Urol 1989; 141:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/26\">",
"      Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis. JAMA 1977; 238:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/27\">",
"      Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/28\">",
"      Stankus N, Worcester E, Hammes M, Coe FL. Evidence against a contribution of conventional urine risk factors to de novo ESRD renal stones. Nephrol Dial Transplant 2006; 21:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/29\">",
"      Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/30\">",
"      Pak CY, Skurla C, Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol 1985; 134:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/31\">",
"      Nicar MJ, Hsu MC, Johnson T, Pak CY. The preservation of urine samples for determination of renal stone risk factors. Lab Med 1987; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/32\">",
"      Hess B, Hasler-Strub U, Ackermann D, Jaeger P. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 1997; 12:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/33\">",
"      Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 2002; 167:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/34\">",
"      Bao Y, Wei Q. Water for preventing urinary stones. Cochrane Database Syst Rev 2012; 6:CD004292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/35\">",
"      Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008; 73:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/36\">",
"      Sandhu C, Anson KM, Patel U. Urinary tract stones--Part I: role of radiological imaging in diagnosis and treatment planning. Clin Radiol 2003; 58:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/37\">",
"      Ferrandino MN, Bagrodia A, Pierre SA, et al. Radiation exposure in the acute and short-term management of urolithiasis at 2 academic centers. J Urol 2009; 181:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29033/abstract/38\">",
"      Zilberman DE, Tsivian M, Lipkin ME, et al. Low dose computerized tomography for detection of urolithiasis--its effectiveness in the setting of the urology clinic. J Urol 2011; 185:910.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7367 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29033=[""].join("\n");
var outline_f28_22_29033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22323234\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE OF STONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Calcium stones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722956\">",
"      - Biochemical risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722984\">",
"      - Predisposing conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Uric acid stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Struvite stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H723012\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Focused history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723082\">",
"      Radiologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723192\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H723435\">",
"      - Limited evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H723460\">",
"      - Complete metabolic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H723485\">",
"      - Targeted approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THE COMPLETE METABOLIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H723806\">",
"      - Urine calcium-creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      24-hour urine collections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Number of collections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Timing of collections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT IF STONE COMPOSITION IS UNKNOWN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723846\">",
"      Hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723853\">",
"      Hypocitraturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723861\">",
"      Hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723868\">",
"      Hyperuricosuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H729457\">",
"      Low urine volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      No obvious metabolic abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178189\">",
"      Use of calculated supersaturations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H724201\">",
"      RADIOLOGIC MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22323234\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7367|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/7/43123\" title=\"diagnostic image 1A\">",
"      KUB showing staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/47/21233\" title=\"diagnostic image 1B\">",
"      CT scan showing large renal pelvic stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/41/6804\" title=\"diagnostic image 2\">",
"      Kidney stone detected by ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7367|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/29/25053\" title=\"figure 1\">",
"      Protein intake and stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/29/14813\" title=\"figure 2\">",
"      Stone recurrence rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/21/40285\" title=\"figure 3\">",
"      Urinary collections and stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7367|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35439\" title=\"picture 1\">",
"      Struvite crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2208\" title=\"picture 2\">",
"      Cystine crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/50/11040\" title=\"picture 3A\">",
"      Uric acid crystals in the urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/51/21309\" title=\"picture 3B\">",
"      Uric acid crystals under polarized light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42302\" title=\"picture 4A\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10561\" title=\"picture 4B\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/23/21877\" title=\"picture 5\">",
"      Indinavir crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/35/1596\" title=\"table 1\">",
"      Risk factors for calcium stones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=related_link\">",
"      Clinical significance of residual stone fragments following stone removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=related_link\">",
"      The first kidney stone and asymptomatic nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29034="Pulmonary complications of inflammatory bowel disease";
var content_f28_22_29034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications of inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/22/29034/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/22/29034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) is associated with a variety of conditions outside of the gastrointestinal tract, termed extraintestinal manifestations of IBD (",
"    <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"     table 1",
"    </a>",
"    ). Since the original report in 1976 of six patients with unexplained chronic purulent sputum production, involvement of the respiratory tract, although relatively rare, has been increasingly recognized in patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulmonary complications of IBD including those related to the medications used to treat IBD are discussed here. An approach to the evaluation and diagnosis of interstitial pneumonia and discussions of the clinical manifestations of Crohn's disease and ulcerative colitis are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16435177\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series vary in terms of the proportions of patients with ulcerative colitis and Crohn&rsquo;s disease who have associated lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In a series of 52 patients with IBD, abnormal pulmonary function tests were more common in patients with Crohn&rsquo;s disease than ulcerative colitis (25 versus 6 percent), but abnormal computed tomography was seen in approximately 50 percent of patients with ulcerative colitis or Crohn&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/3\">",
"     3",
"    </a>",
"    ]. In a separate series of 33 patients with IBD-associated lung involvement, 27 had ulcerative colitis and six had Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987388\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of pulmonary parenchymal disease and serositis associated with IBD is unknown. However, the more common airway inflammatory changes are thought to represent the same type of inflammatory changes that occur in the bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621233\">",
"    <span class=\"h1\">",
"     PRIMARY RESPIRATORY INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications of IBD include inflammation of small and large airways, pulmonary parenchymal disease, serositis, and pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These abnormalities are generally related to the underlying bowel disease, although interstitial lung disease can also be induced by administration of certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , 5-aminosalicylic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Patients with IBD may present with cough, dyspnea, chest pain, or an abnormal chest radiograph obtained for another reason. Often the initial history (including current medications) and physical examination will focus attention on a given type of lung involvement (eg, airway versus parenchymal).",
"   </p>",
"   <p>",
"    The three main patterns of presentation (airway disease, parenchymal disease, and serositis) have somewhat different characteristics in terms of sex preponderance and activity of the bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A female preponderance of almost 2:1 is reported for bronchopulmonary complications as a whole and approximately 3:1 for bronchial complications. In contrast, serositis occurs with roughly equal frequency in men and women.",
"     </li>",
"     <li>",
"      Bronchopulmonary complications follow the onset of inflammatory bowel disease in 80 to 85 percent of patients, precede bowel disease in 10 to 15 percent, and develop concomitantly in 5 to 10 percent. Almost one-half the patients with airway disease have undergone colectomy; in some cases, development of airway symptoms follows colectomy by days to weeks.",
"     </li>",
"     <li>",
"      The majority of patients with serositis have active inflammatory bowel disease, while parenchymal lung disease often develops in the setting of inactive bowel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987945\">",
"    <span class=\"h2\">",
"     Airway involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease is associated with inflammation of the trachea, bronchi, and bronchioles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,5,13-15\">",
"     2,5,13-15",
"    </a>",
"    ]. In a review of 131 cases of respiratory involvement in IBD, approximately 41 percent presented with some form of airway inflammation (",
"    <a class=\"graphic graphic_table graphicRef54855 \" href=\"UTD.htm?9/31/9724\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. The types of airway involvement in IBD include bronchiectasis, which is the most common, acute and chronic tracheobronchitis, bronchiolitis, subglottic stenosis, and fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,12\">",
"     2,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with IBD-associated bronchitis or bronchiectasis typically present with cough and variable amounts of mucopurulent sputum production [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/16\">",
"       16",
"      </a>",
"      ]. Cultures of bronchial secretions are unrevealing, and the symptoms unresponsive to antibiotics. Chest radiographs are frequently normal or show nonspecific changes resulting from bronchial wall thickening or bronchiectasis. High resolution chest computed tomography (HRCT) scanning is more sensitive than conventional chest radiographs, often demonstrating findings of bronchial wall thickening, dilated airways with thickened walls, or branched opacities suggestive of mucoid impaction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      On pulmonary function testing, an obstructive impairment with a reduced or normal forced vital capacity (FVC), a low forced expiratory volume (FEV1), and a low",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      is the most frequent finding. In contrast to asthma, however, airflow obstruction does not show significant reversibility following inhaled bronchodilator, and bronchoprovocation challenge (eg, histamine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      ) does not reveal airway hyperresponsiveness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small airway involvement (eg, bronchiolitis) can cause cough, variable sputum production, wheezing, and airflow obstruction. Pathologic findings include nonspecific inflammation, narrowing, and fibrosis of the small airways; granulomatous bronchiolitis has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10,19\">",
"       10,19",
"      </a>",
"      ]. Small airway involvement with IBD is associated with abnormalities in pulmonary function (eg, airflow obstruction and reduced diffusing capacity). The clinical manifestations of bronchiolitis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subglottic stenosis is associated with inflammation, friability, and inflammatory pseudotumors in the trachea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. The primary symptoms are cough and dysphonia, although some patients develop upper airway obstruction with resulting stridor and severe dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/22\">",
"       22",
"      </a>",
"      ]. A flow-volume loop may show variable extrathoracic obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link&amp;anchor=H4#H4\">",
"       \"Flow-volume loops\", section on 'Variable extrathoracic obstruction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteric-pulmonary fistulas, such as colo-bronchial, ileo-bronchial, and esophago-bronchial, have been described in patients with Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10,23\">",
"       10,23",
"      </a>",
"      ]. In a series of over 400 patients with IBD, five patients with colobronchial fistulae were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10\">",
"       10",
"      </a>",
"      ]. Four had left lower lobe pneumonia; clinical findings included fever, radiographic opacities, pleural effusion, and growth of enteric pathogens on culture. Esophageal Crohn disease is rare, but four cases of esophago-bronchial fistulae have been reported. These patients complained of dysphagia and had clinical evidence of pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary parenchymal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with respiratory involvement with IBD, approximately 27 percent have lung parenchymal disease (",
"    <a class=\"graphic graphic_table graphicRef54855 \" href=\"UTD.htm?9/31/9724\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. Several patterns of lung parenchymal involvement have been described in IBD, with organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia) and interstitial lung disease (not otherwise specified) being most common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,8,12\">",
"     2,8,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung infections should be considered in the differential diagnosis of pulmonary parenchymal disease in patients with IBD, particularly when patients present with fever, dyspnea, cough, and radiographic opacities. Information about community-acquired pneumonia and pneumonia in immunocompromised hosts is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987815\">",
"    <span class=\"h3\">",
"     Abnormalities in pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have indentified abnormalities in pulmonary function tests among patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/3,11,24,25\">",
"     3,11,24,25",
"    </a>",
"    ]. In a series of 82 patients with IBD and normal plain chest radiographs, 47 (57 percent) had abnormal findings on pulmonary function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of these patients had findings consistent with restrictive lung disease and a reduced diffusing capacity. A separate series of 85 patients with ulcerative colitis and 47 patients with Crohn's disease found that diffusing capacity was significantly lower during exacerbations of bowel disease than when gastrointestinal disease was quiescent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/24\">",
"     24",
"    </a>",
"    ]. No pulmonary symptoms were associated with these transient physiologic derangements. These results have been confirmed in other reports, suggesting that mild pulmonary inflammation commonly accompanies inflammation of the bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987822\">",
"    <span class=\"h3\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organizing pneumonia (OP) presents in an acute or subacute fashion with variable combinations of fever, dyspnea, cough, and pleuritic chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. OP can also be a manifestation of drug-induced lung toxicity. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug-induced complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H3#H3\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest radiographic findings range from patchy focal consolidation to diffuse opacities; high resolution computed tomography (HRCT) scanning often demonstrates peripheral ground-glass opacities or areas of consolidation that may have an air bronchogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H6#H6\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Chest imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987829\">",
"    <span class=\"h3\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD) in IBD is thought to reflect a spectrum of diseases, such as organizing pneumonia, nonspecific interstitial pneumonia, desquamative interstitial pneumonia (typically in smokers), eosinophilic pneumonia and usual interstitial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/12\">",
"     12",
"    </a>",
"    ]. When mild or not progressive, it is often not evaluated histopathologically, so the exact type of ILD is not always identified. Drug-induced pulmonary toxicity is an important cause of ILD among patients with IBD. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug-induced complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical presentation of ILD is generally characterized by a subacute onset of dyspnea, crackles on chest examination, and radiographic findings of diffuse ground glass or reticular opacities, most prominent at the lung bases. Patients may have a stable course or manifest progressive respiratory insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bronchoalveolar lavage (BAL) fluid in IBD-associated ILD is usually lymphocytic. An elevated CD4:CD8 ratio in the BAL, a characteristic finding in sarcoidosis, has also been documented in patients with Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/12,26,27\">",
"     12,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987836\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cases of sarcoidosis coexisting with ulcerative colitis or Crohn&rsquo;s disease have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10,26,28\">",
"     10,26,28",
"    </a>",
"    ]. No clear etiologic association has been identified between inflammatory bowel disease and sarcoidosis. However, it has been suggested that there may be a pathogenetic relationship between sarcoidosis and Crohn's disease, since bronchoalveolar lavage fluid lymphocytosis (with elevated",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratios) and noncaseating granulomas in lung tissue can be seen in both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, four reports of the coexistence of Crohn&rsquo;s disease and sarcoidosis in siblings suggest a potential genetic overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/10\">",
"     10",
"    </a>",
"    ]. The clinical and radiographic manifestations of sarcoidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987843\">",
"    <span class=\"h3\">",
"     Pulmonary infiltrates with eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary infiltrates with eosinophilia (PIE) syndrome is a recognized complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , which is commonly used in the therapy of ulcerative colitis. There are also case reports of eosinophilic pneumonia in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/9,29-31\">",
"     9,29-31",
"    </a>",
"    ]. However, the PIE syndrome can occur in patients with inflammatory bowel disease who have no history of using these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/7\">",
"     7",
"    </a>",
"    ]. Eosinophilia is frequently present in the peripheral blood, and chest radiographs often show patchy peripheral opacities typical of chronic eosinophilic pneumonia. Bronchoalveolar lavage (BAL) eosinophilia is frequently present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Eosinophilic BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987850\">",
"    <span class=\"h3\">",
"     Necrobiotic nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, necrobiotic lung nodules are described in patients with IBD. The nodules have a radiographic resemblance to the cavitating nodules seen with septic pulmonary emboli or granulomatosis with polyangiitis (Wegener&rsquo;s) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70948 \" href=\"UTD.htm?0/37/597\">",
"     image 1",
"    </a>",
"    ). Histologically, the nodules are composed of sterile aggregates of neutrophils with necrosis, findings that are similar to those of pyoderma gangrenosum, a cutaneous complication of inflammatory bowel disease (",
"    <a class=\"graphic graphic_picture graphicRef60375 \" href=\"UTD.htm?31/50/32545\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/32\">",
"     32",
"    </a>",
"    ]. In isolated case reports, the clinical presentation has included fever, cough, weight loss, and a flare of intestinal Crohn&rsquo;s disease; in one patient concomitant cutaneous pyoderma gangrenosum was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a rare complication of inflammatory bowel disease, serositis involving intrathoracic structures has occurred in the form of pleural effusions, pericarditis, pleuropericarditis, and myopericarditis (",
"    <a class=\"graphic graphic_table graphicRef54855 \" href=\"UTD.htm?9/31/9724\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,10,34\">",
"     2,10,34",
"    </a>",
"    ]. Patients typically present with chest pain. The serosal fluid is exudative, with a cellular content generally composed primarily of neutrophils.",
"   </p>",
"   <p>",
"    Drugs are another potential cause of serositis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , commonly used medications for IBD, have been associated with pleural effusions, although not particularly in patients with IBD. A lupus-like syndrome sometimes with serositis has been reported in 10 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/36\">",
"     36",
"    </a>",
"    ]. All of the patients had a positive antinuclear antibody, some had a positive anti-double stranded DNA antibody, and three had a positive antihistone antibody, although it was not clear whether antihistone antibody testing was done in other patients. Symptoms and autoantibodies improved with discontinuation of the medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IBD may be at increased risk for venous thromboembolism (VTE) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/12,37-47\">",
"     12,37-47",
"    </a>",
"    ]. In a cohort study, 49,799 patients with IBD were compared with 477,504 members of the general population, and IBD was associated with an increased risk of VTE (HR 2.0, 95% CI 1.8 to 2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/47\">",
"     47",
"    </a>",
"    ]. In a case control study comparing patients with chronic thromboembolic pulmonary hypertension versus acute pulmonary embolism, IBD was a significant risk factor for chronic thromboembolic pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/38\">",
"     38",
"    </a>",
"    ]. It is thought that patients with IBD have several risk factors for hypercoagulability, although no particular laboratory test has sufficient predictive value to identify patients at increased risk (",
"    <a class=\"graphic graphic_table graphicRef68675 \" href=\"UTD.htm?32/51/33595\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689099#H12689099\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Extraintestinal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link&amp;anchor=H1844647817#H1844647817\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\", section on 'Extraintestinal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DRUG-INDUCED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad spectrum of pulmonary disease has been described associated with drugs used to treat IBD. Most of the drugs have been implicated, including the more commonly used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and 5-aminosalicylic acid (5-ASA) and the less commonly used agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercaptopurine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/9,29,48\">",
"     9,29,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Groupes d'Etudes de la Pathologie Pulmonaire Iatrog&egrave;ne maintains a frequently updated website listing drugs that have been associated with pulmonary infiltrates and a list of references (",
"    <a class=\"external\" href=\"file://www.pneumotox.com/\">",
"     www.pneumotox.com",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis, commonly in conjunction with fever and rash, is a recognized complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    therapy. Nearly half of affected patients present with the clinical syndrome of pulmonary infiltrates with eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/9\">",
"     9",
"    </a>",
"    ]. Cough and crackles on lung examination were commonly reported. Eosinophil counts in the peripheral blood ranged from 432 to",
"    <span class=\"nowrap\">",
"     7500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other pulmonary disorders associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    include nonspecific interstitial pneumonia, organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), granulomatous lung disease, and rarely pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. A pulmonary picture consistent with granulomatosis with polyangiitis (Wegener&rsquo;s) has also been attributed to sulfasalazine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     5-aminosalicylic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity attributable to 5-aminosalicylic acid (5-ASA or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ) is less common than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . Affected patients may have diffuse or patchy basilar opacities on high resolution computed tomography (HRCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/48,52\">",
"     48,52",
"    </a>",
"    ]. Histopathologic patterns of inflammation include pulmonary eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/29\">",
"     29",
"    </a>",
"    ], organizing pneumonia, and bronchiolitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/31,48\">",
"     31,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung toxicity from MTX may have an acute, subacute, or chronic presentation; typical symptoms include nonproductive cough, dyspnea, fever, and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/31,53\">",
"     31,53",
"    </a>",
"    ]. Chest HRCT patterns associated with MTX toxicity include patchy ground glass or consolidative opacities, diffuse ground glass with or without reticulation, micronodules, and bilateral basilar reticular opacities. In one patient, lymphocytic bronchoalveolar lavage fluid was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/54\">",
"     54",
"    </a>",
"    ]. Histopathologic findings include organizing pneumonia, diffuse alveolar damage, pulmonary fibrosis, granulomatous inflammation, eosinophilic pneumonitis, and nonspecific interstitial pneumonia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    -induced pulmonary injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    has also been associated with drug-induced pleural effusion. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Serositis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Azathioprine and 6-mercaptopurine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulatory drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and 6-mercaptopurine (6-MP), can potentiate the therapeutic effect of glucocorticoids and exert a glucocorticoid-sparing effect in patients with glucocorticoid-dependent ulcerative colitis. Drug-induced hypersensitivity pneumonitis is a rare but potentially serious complication of therapy with these agents, although it is more commonly reported in patients taking AZA for renal transplant immunosuppression than for IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/23,55,56\">",
"     23,55,56",
"    </a>",
"    ]. Clinical manifestations include dyspnea, cough, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link&amp;anchor=H9#H9\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other pathologic patterns, such as usual interstitial pneumonia and organizing pneumonia (formerly known as bronchiolitis obliterans with organizing pneumonia), have rarely been reported in patients with inflammatory bowel disease treated with AZA or 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    , an inhibitor of tumor necrosis factor-alpha, is used in selected patients with Crohn's disease, particularly those with fistulizing disease. Infectious complications from use of infliximab are well-described, most notably the development of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/57\">",
"     57",
"    </a>",
"    ]. There are also case reports of interstitial pneumonitis developing in patients with rheumatoid arthritis or Crohn's disease treated with infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. In some patients the pattern was consistent with drug-induced lupus and in others with usual interstitial pneumonia, nonspecific interstitial pneumonia, or organizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The risk of infliximab-associated pneumonitis appears greater among patients of older age or with a history of preexisting lung disease, although these risk factors are not always present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    has also been associated with development of serositis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Serositis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16433751\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and diagnosis of pulmonary complications of inflammatory bowel disease usually starts with an assessment of the severity of dyspnea, rapidity of onset of symptoms, and presence of medications that are known to cause lung toxicity or immunosuppression. For patients with a rapid onset of dyspnea, fever, or respiratory distress, pulmonary embolism, pneumonia, and drug toxicity should be evaluated promptly. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    For patients with a more indolent onset of disease, the workup usually starts with a complete blood count and differential, antinuclear antibodies and antihistone antibodies if drug-induced lung disease is suspected, pulmonary function testing (PFT), and a conventional chest radiograph. Further studies depend on the results of the initial studies and the suspected site of involvement. The following are some examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5620986\">",
"    <span class=\"h2\">",
"     Airway involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of airway involvement with inflammatory bowel disease is often based on the clinical presentation of cough and sputum production in a patient without evidence of an infectious tracheobronchitis or asthma. In patients with chronic bronchitis, bronchiectasis, or bronchiolitis, pulmonary function tests usually reveal airflow obstruction, but in contrast to asthma do not show significant reversibility following inhaled bronchodilator or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    hyperresponsiveness. (See",
"    <a class=\"local\" href=\"#H112987945\">",
"     'Airway involvement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Pulmonary function testing'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The diagnosis of bronchiectasis is usually based on the presence of typical chest high resolution computed tomography (HRCT) findings of airway dilation (ie, 1.5 times the diameter of the adjacent vessel or wider), often accompanied by bronchial wall thickening. (See",
"    <a class=\"local\" href=\"#H112987945\">",
"     'Airway involvement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Computed tomography'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The diagnosis of bronchiolitis is suggested when airflow limitation is irreversible and associated with a gas transfer abnormality in a nonsmoker. The most consistent abnormalities on HRCT are expiratory air trapping (mosaic or diffuse) and bronchiolar wall thickening (eg, centrilobular nodules and &ldquo;tree-in-bud&rdquo; opacities). In addition, a pattern of diffuse ground glass opacity with a mosaic pattern of attenuation is seen in some patients. A firm diagnosis of bronchiolitis requires an open or thoracoscopic lung biopsy. (See",
"    <a class=\"local\" href=\"#H112987945\">",
"     'Airway involvement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H11#H11\">",
"     \"Bronchiolitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tracheal involvement, suggested by the combination of dyspnea on exertion and a clear conventional chest radiograph (with or without stridor), is evaluated with a flow-volume loop; flattening of the inspiratory loop suggests extrathoracic variable obstruction (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 1",
"    </a>",
"    ). The expiratory loop may be normal. High resolution computed tomography of the trachea with three-dimensional reconstruction can provide additional support with visualization of the degree and extent of airway narrowing. The diagnosis is confirmed by direct visualization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link&amp;anchor=H5#H5\">",
"     \"Flow-volume loops\", section on 'Variable intrathoracic obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Direct visualization via flexible bronchoscopy is generally not necessary for lower airway involvement unless airway compromise is suspected or the patient has hemoptysis. Irregular and erythematous mucosa, exuberant inflammatory tissue, ulcerations, and narrowing of the airways have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5620994\">",
"    <span class=\"h2\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with interstitial lung disease associated with IBD, several processes must be differentiated: interstitial lung disease, sarcoidosis, drug-induced disease, superimposed infection, and concomitant connective tissue disease (eg, lupus). After a careful review of the history of medication use and potential exposures to infectious agents, the evaluation typically involves laboratory testing to assess for peripheral blood eosinophilia and antinuclear antibody positivity, pulmonary function testing to assess the severity of restrictive impairment, and high resolution computed tomography (HRCT) of the lungs to determine the pattern and distribution of opacities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The combination of diffuse pulmonary opacities and peripheral eosinophilia creates a high suspicion for drug-induced lung disease, although eosinophilic pneumonias are seen in patients with IBD without a drug association and fungal pneumonia and tropical filarial infection can also cause eosinophilia, particularly in endemic areas. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug-induced complications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H112987829\">",
"     'Interstitial lung disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the patient with eosinophilia\", section on 'Fungal infections'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Flexible bronchoscopy with bronchoalveolar lavage (BAL) is typically performed to obtain samples for cell counts, microbiologic stains and cultures, and cytology. The BAL findings are more helpful in excluding processes such as infection or malignancy than in confirming a specific type of interstitial lung disease, although an eosinophilic BAL in a patient with IBD is more likely to be drug-induced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    For patients with significant respiratory impairment or evidence of progressive deterioration in lung function, further evaluation typically includes lung biopsy via thoracoscopy or thoracotomy. The main role for lung biopsy is to characterize the histopathologic pattern and to exclude other processes, such as tumor or infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621002\">",
"    <span class=\"h2\">",
"     Serositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with pleuritic type chest pain or radiographic evidence of pleural or other serosal involvement, it is important to exclude infection, particularly in patients taking immunosuppressive agents. Laboratory testing (eg, antinuclear antibodies, antihistone antibodies, antidouble-stranded DNA antibodies) may be indicated to look for drug-induced lupus or a concomitant connective tissue disease. A diagnostic thoracentesis is typically performed to exclude infection or malignancy if an adequate amount of free-flowing pleural fluid is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621010\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for suspected thromboembolic disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    For patients with an insidious onset of dyspnea, hypoxemia on exertion, a reduced diffusing capacity, and relative lung parenchymal sparing may have chronic thromboembolic pulmonary hypertension. Transthoracic echocardiography shows elevated pulmonary artery pressures, which can be confirmed with right heart catheterization. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pulmonary embolism'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621018\">",
"    <span class=\"h2\">",
"     Drug-induced interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of drug-induced interstitial lung disease (ILD) is supported by the presence of eosinophilia in the peripheral blood, bronchoalveolar lavage, or lung tissue. Alternative diagnoses include infectious and inflammatory causes of ILD. In the absence of eosinophilia, the diagnosis is based on the clinical presentation (eg, clinical syndrome of drug-induced lupus versus atypical pneumonia), the likelihood of the drug in question causing lung toxicity, exclusion of other etiologies, and a trial of drug discontinuation (dechallenge). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link&amp;anchor=H11#H11\">",
"     \"Methotrexate-induced lung injury\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Lung biopsy is occasionally necessary when the diagnosis is unclear. A variety of histopathologic patterns have been associated with agents used to treat IBD, including virtually all of the idiopathic interstitial lung diseases. Organizing pneumonia on histopathology can be drug-induced or associated with the underlying IBD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Role of lung biopsy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H112987822\">",
"     'Organizing pneumonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of the various pulmonary complications of IBD depends on the site, severity, and type of involvement. The activity of the underlying IBD does not always correlate with the activity of lung involvement, so lung involvement is often treated independently. If the IBD is flaring at the same time as the lung involvement, therapy is tailored to achieve a combination that will address both processes. If the patient has a drug-induced pulmonary toxicity, the treatment of the IBD will need to be changed to an alternate agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8794801\">",
"    <span class=\"h2\">",
"     Airway involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway compromise due to subglottic stenosis requires urgent attention to secure the airway via endotracheal intubation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rigid bronchoscopy. Additional airway interventions such as dilation, laser therapy, or stenting depend on the assessment of the airway at the time of bronchoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with potentially life-threatening airway inflammation, such as subglottic stenosis, are typically treated with systemic glucocorticoids, based on clinical experience rather than clinical trial data [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. We usually start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lean body weight per day to a maximum of 60 mg per day, given as a single oral dose in the morning. For patients who are unable to take oral medication, an intravenous preparation is substituted, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    60 to 80 mg in divided doses. As the airway inflammation improves, intravenous glucocorticoids are changed to oral and then inhaled preparations.",
"   </p>",
"   <p>",
"    For patients who have IBD-associated airway involvement without immediate airway compromise, inhaled glucocorticoid therapy is frequently effective, although formal data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. In a case series, among 12 patients treated with inhaled glucocorticoids, nine had a significant improvement, but three experienced progressive and disabling disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. Relatively high doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    1500 to 2000",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    were needed in some patients. We typically start with the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    500 mcg twice daily and adjust based on the response to therapy. &nbsp;Inflammation in the larger airways tends to be more responsive than bronchiolitis, possibly due to relatively poor delivery of the inhaled medication to the affected small airways. Patients with copious sputum production (greater than 50",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    and those with bronchiectasis are less likely to respond to inhaled glucocorticoids and may require oral glucocorticoids. After excluding an infectious cause for sputum production, we usually add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lean body weight per day to a maximum of 60 mg per day, given as a single oral dose in the morning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H15#H15\">",
"     \"Bronchiolitis in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enteric-bronchial fistulae typically require systemic antibiotics to treat associated pulmonary parenchymal infection and then surgical resection to prevent recurrence. The treatment of fistulae due to Crohn&rsquo;s disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188328#H11188328\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Fistulae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=see_link&amp;anchor=H3869852#H3869852\">",
"     \"Operative management of Crohn's disease of the small bowel and colon\", section on 'Fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8794843\">",
"    <span class=\"h2\">",
"     Pulmonary parenchymal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients with pulmonary parenchymal complications of IBD generally require oral glucocorticoid therapy, once infection and drug-induced disease have been excluded. Management is typically based on the underlying histopathology. Thus, treatment of organizing pneumonia, eosinophilic pneumonia, nonspecific interstitial pneumonia, or sarcoidosis would follow treatment recommendations for these diseases, most of which are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at an initial dose of 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, up to a daily dose of 60 mg. The higher initial doses are usually chosen for patients with more severe lung involvement and for noneosinophilic conditions; lower doses are usually adequate for eosinophilic lung diseases and sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link&amp;anchor=H12#H12\">",
"     \"Idiopathic acute eosinophilic pneumonia\", section on 'Treatment and outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link&amp;anchor=H16#H16\">",
"     \"Nonspecific interstitial pneumonia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of systemic glucocorticoid treatment has not been established, but generally is based on the response to therapy and the timing of tapering established for the underlying histopathology. In general, for patients who respond or stabilize with treatment, the",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/prednisone-drug-information?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;dose is gradually tapered, aiming to reach 5 to 10 mg daily or on alternate days, by the end of 6 months, with attempted cessation after one year of therapy.",
"   </p>",
"   <p>",
"    Most patients with parenchymal lung disease due to IBD have a good response to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"     2",
"    </a>",
"    ]. However, for those with progressive pulmonary dysfunction despite therapy with systemic glucocorticoids, immunomodulatory therapy is usually added. For patients with ongoing need for immunomodulatory therapy to control their IBD, the optimal agent to control their IBD is usually chosen. However, if the patient&rsquo;s IBD is not active, the choice of a second-line agent is based on the specific underlying lung histopathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94183192\">",
"    <span class=\"h2\">",
"     Serositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After exclusion of infectious processes, patients who have symptoms caused by pleuritis, pericarditis, or myopericarditis due to IBD are typically treated with a nonsteroidal antiinflammatory drug (NSAID), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 to 800 mg three times daily, unless the IBD is active and the patient is at risk for gastrointestinal bleeding. NSAIDs have been used successfully in other forms of inflammatory serositis, although the experience in patients with IBD is limited. Systemic glucocorticoid therapy is an alternative if the patient does not respond to NSAIDs or is unable to take them. Based on experience with recurrent pericarditis, we typically initiate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.2 to",
"    <span class=\"nowrap\">",
"     0.5mg/Kg/day;",
"    </span>",
"    ie, 25mg for the average patient) for four weeks and then taper as tolerated. As NSAID therapy can precipitate a flare of IBD, careful patient education and close follow up is needed during NSAID therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H10#H10\">",
"     \"Recurrent pericarditis\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link&amp;anchor=H531100138#H531100138\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\", section on 'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8794815\">",
"    <span class=\"h2\">",
"     Pulmonary thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with IBD, the choice of treatment of acute pulmonary thromboembolism depends on the expected risk of gastrointestinal bleeding. For patients with active IBD, especially with significant bleeding, an inferior vena cava filter is usually inserted and anticoagulation deferred until the IBD is under control. If the patient is not deemed to be at increased risk for gastrointestinal bleeding, the usual guidelines for anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    are followed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Initiation of anticoagulant therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112987881\">",
"    <span class=\"h2\">",
"     Drug-induced lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients taking a medication for IBD that has been associated with pulmonary toxicity who present with fever, cough, and radiographic opacities, appropriate antimicrobial therapy is usually initiated. In addition, the implicated drug is empirically discontinued, while awaiting culture results and a response to drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. Drug-induced lung inflammation and peripheral blood eosinophilia, if present, usually resolve with drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link&amp;anchor=H18#H18\">",
"     \"Methotrexate-induced lung injury\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with severe respiratory insufficiency due to drug-induced pulmonary disease or lack of improvement with drug discontinuation, we initiate therapy with systemic glucocorticoids. This choice is based on clinical experience, as clinical data in support of this therapy are lacking. The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in a single morning dose. For patients who have had an episode of drug-induced pulmonary toxicity, we avoid reintroduction of that agent.",
"   </p>",
"   <p>",
"    When it is unclear whether a particular drug contributed to the lung injury, decisions concerning cessation of drug therapy should consider the availability of alternative agents and the relative severity of the pulmonary disease and the IBD, which could flare if the drug is withdrawn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272016037\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether patients with IBD would benefit from prophylaxis against venous thromboembolism (VTE) during hospitalization, given the increased risk for VTE in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/22/29034/abstract/12,37-41\">",
"     12,37-41",
"    </a>",
"    ]. Unfortunately, data to guide prophylaxis in this subset of patients are lacking. Our approach is to base the decision for mechanical or pharmacologic thromboprophylaxis on the clinical situation.",
"   </p>",
"   <p>",
"    As an example, a patient with IBD who is older than age 40, hospitalized with an acute medical illness, and expected to have limited mobility for &ge;3 days is considered to be at increased risk for VTE. The choice about the method of prophylaxis is then largely based on the anticipated risk of bleeding; those at increased risk of bleeding (eg active IBD) are managed with mechanical thromboprophylaxis, while those without an increased risk of bleeding are managed with pharmacologic prophylaxis according to current guidelines. The prevention of VTE in medical patients is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H31#H31\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical patients with IBD are considered to be at increased risk for VTE, but decisions about prophylaxis need to consider the nature of the planned surgical procedure and how much a given procedure increases the risk of VTE. For surgical patients with IBD but without evidence of gastrointestinal bleeding or other contraindications to anticoagulation, the standard guidelines for VTE prophylaxis are followed. On the other hand, for those patients considered to be at increased risk for bleeding, mechanical methods of thromboprophylaxis are preferred. These choices are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H30#H30\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16433788\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2370939\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary complications of inflammatory bowel disease (IBD), although uncommon, include airway inflammation, parenchymal lung disease, serositis, thromboembolic disease, and drug-induced lung toxicity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with IBD, inflammation of the trachea, bronchi, and bronchioles may develop before or after bowel resection and rarely preceding the onset of IBD. Bronchiectasis is the most common form of airway involvement, but subglottic stenosis, airway-enteral fistulae, bronchitis, and bronchiolitis also occur. (See",
"      <a class=\"local\" href=\"#H112987945\">",
"       'Airway involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several patterns of diffuse lung parenchymal involvement have been described in IBD, including organizing pneumonia, eosinophilic pneumonia, and nonspecific interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary parenchymal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IBD-associated serositis may present with pleural effusions, pericarditis, pleuropericarditis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myopericarditis. The pleural fluid is exudative, with a cellular content composed primarily of neutrophils. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Serositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the drugs used to treat IBD have been implicated in drug-induced pulmonary disease, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , 5-aminosalicylic acid (5-ASA),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-mercaptopurine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . Drug-induced lung diseases associated with these agents include pulmonary infiltrates with eosinophilia (PIE) syndrome, organizing pneumonia, a hypersensitivity syndrome (fever, cough, dyspnea, radiographic opacities), interstitial pneumonitis, reactivation of Mycobacterium tuberculosis, and development of other opportunistic infections. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Drug-induced complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"       \"Methotrexate-induced lung injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"       \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evaluation and diagnosis of pulmonary complications of inflammatory bowel disease usually starts with an assessment of the severity of dyspnea, rapidity of onset of symptoms, and presence of medications that are known to cause lung toxicity or immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a more rapid onset of dyspnea, fever, or respiratory distress, pulmonary embolism, pneumonia, and subglottic stenosis should be evaluated promptly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of acute pulmonary embolism\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"       \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a more indolent onset of disease, the workup usually starts with a complete blood count and differential, antinuclear antibodies and antihistone antibodies if drug-induced lung disease is suspected, pulmonary function testing (PFT), and a conventional chest radiograph. (See",
"      <a class=\"local\" href=\"#H16433751\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with airflow limitation on PFTs, the key next steps are determining the severity of airway compromise, whether subglottic stenosis may be present, and whether reversible airflow obstruction is more suggestive of asthma than IBD-associated airway inflammation. (See",
"      <a class=\"local\" href=\"#H5620986\">",
"       'Airway involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High resolution computed tomography is performed in patients suspected of having bronchiectasis, bronchiolitis, diffuse lung parenchymal disease, or drug-induced lung disease. (See",
"      <a class=\"local\" href=\"#H16433751\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2370950\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of the various pulmonary complications of IBD depends on the site, severity, and type of involvement. The activity of the underlying IBD does not always correlate with the activity of lung involvement, so the lung involvement is often treated independently. If the IBD is flaring at the same time as the lung involvement, therapy is tailored to achieve a combination that will address both processes simultaneously. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway compromise due to subglottic stenosis requires urgent attention to secure the airway via endotracheal intubation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rigid bronchoscopy. Additional airway interventions such as dilation, laser therapy, or stenting depend on the assessment of the airway at the time of bronchoscopy. &nbsp;In addition, we suggest initiation of systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual dose is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      lean body weight per day to a maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      given as a single oral dose in the morning. Systemic glucocorticoids are tapered and transitioned to inhaled glucocorticoids as the patient improves. (See",
"      <a class=\"local\" href=\"#H8794801\">",
"       'Airway involvement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have IBD-associated airway involvement without immediate airway compromise, we suggest initial administration of inhaled glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Relatively high doses of an inhaled glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      1500 to 2000",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      500 to 1000",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      may be needed. For patients who do not have an adequate response to inhaled glucocorticoid therapy, we suggest initiation of systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We usually start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      lean body weight per day to a maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      given as a single oral dose in the morning. (See",
"      <a class=\"local\" href=\"#H8794801\">",
"       'Airway involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating pulmonary parenchymal disease based on the underlying histopathology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an example, treatment of organizing pneumonia, eosinophilic pneumonia, nonspecific interstitial pneumonia, or sarcoidosis would follow treatment recommendations for these diseases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary parenchymal disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"       \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link\">",
"       \"Treatment of chronic eosinophilic pneumonia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"       \"Idiopathic acute eosinophilic pneumonia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link&amp;anchor=H12#H12\">",
"       \"Idiopathic acute eosinophilic pneumonia\", section on 'Treatment and outcome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of chronic eosinophilic pneumonia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link&amp;anchor=H16#H16\">",
"       \"Nonspecific interstitial pneumonia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"       \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with IBD-associated serositis whose IBD does not place them at increased risk for gastrointestinal bleeding, we suggest initial therapy with a nonsteroidal antiinflammatory drug (NSAID), (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      600 mg three times daily or the equivalent. However, NSAID therapy may exacerbate underlying IBD, so ongoing monitoring is needed. Systemic glucocorticoid therapy is an alternative if the patient does not respond to NSAIDs. (See",
"      <a class=\"local\" href=\"#H94183192\">",
"       'Serositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with IBD and suspected drug-induced lung toxicity due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , 5-aminosalicylic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-mercaptopurine, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , the first step is to discontinue the culprit drug (dechallenge). Improvement following drug discontinuation supports a drug-induced process. (See",
"      <a class=\"local\" href=\"#H112987881\">",
"       'Drug-induced lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with drug-induced lung toxicity who present with severe respiratory insufficiency or have an incomplete response to drug discontinuation, we suggest initiation of oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is usually 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day up to 60 mg in a single morning dose. Rechallenge with a culprit drug is avoided, although data on the exact risk of recurrent lung disease are lacking. (See",
"      <a class=\"local\" href=\"#H112987881\">",
"       'Drug-induced lung disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/1\">",
"      Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/2\">",
"      Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/3\">",
"      Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg 2006; 69:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/4\">",
"      Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/5\">",
"      Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax 1980; 35:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/6\">",
"      Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/7\">",
"      Sostegni R, Daperno M, Pera A. Pulmonary manifestations of inflammatory bowel disease. Dig Liver Dis 2007; 39:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/8\">",
"      Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/9\">",
"      Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/10\">",
"      Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/11\">",
"      Kuzela L, Vavrecka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999; 46:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/12\">",
"      Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/13\">",
"      Kuniar T, Sleiman C, Brugi&egrave;re O, et al. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/14\">",
"      Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med 2000; 161:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/15\">",
"      Bayraktaroglu S, Basoglu O, Ceylan N, et al. A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis. J Crohns Colitis 2010; 4:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/16\">",
"      Camus P, Colby TV. Bronchiectasis in inflammatory bowel disease. Eur Respir Monogr 2011; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/17\">",
"      Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/18\">",
"      Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/19\">",
"      Vandenplas O, Casel S, Delos M, et al. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/20\">",
"      Kirkcaldy J, Lim WS, Jones A, Pointon K. Stridor in Crohn disease and the use of infliximab. Chest 2006; 130:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/21\">",
"      Plataki M, Tzortzaki E, Lambiri I, et al. Severe airway stenosis associated with Crohn's disease: case report. BMC Pulm Med 2006; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/22\">",
"      Janssen WJ, Bierig LN, Beuther DA, Miller YE. Stridor in a 47-year-old man with inflammatory bowel disease. Chest 2006; 129:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/23\">",
"      Casella G, Villanacci V, Di Bella C, et al. Pulmonary diseases associated with inflammatory bowel diseases. J Crohns Colitis 2010; 4:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/24\">",
"      Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med 1998; 92:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/25\">",
"      Marvisi M, Borrello PD, Brianti M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/26\">",
"      Smi&eacute;jan JM, Cosnes J, Chollet-Martin S, et al. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/27\">",
"      Bewig B, Manske I, B&ouml;ttcher H, et al. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/28\">",
"      Theodoropoulos G, Archimandritis A, Davaris P, et al. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/29\">",
"      Tanigawa K, Sugiyama K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/30\">",
"      Saltzman K, Rossoff LJ, Gouda H, Tongia S. Mesalamine-induced unilateral eosinophilic pneumonia. AJR Am J Roentgenol 2001; 177:257.",
"     </a>",
"    </li>",
"    <li>",
"     Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwatrz MI, King TE, Jr.  (Eds), People's Publishing House, Shelton, CT 2011. p.637.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/32\">",
"      Kasuga I, Yanagisawa N, Takeo C, et al. Multiple pulmonary nodules in association with pyoderma gangrenosum. Respir Med 1997; 91:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/33\">",
"      Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can J Gastroenterol 2004; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/34\">",
"      Rosenbaum AJ, Murphy PJ, Engel JJ. Pleurisy during the course of ulcerative colitis. J Clin Gastroenterol 1983; 5:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/35\">",
"      Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/36\">",
"      Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/37\">",
"      Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/38\">",
"      Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/39\">",
"      Quera R, Shanahan F. Thromboembolism--an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/40\">",
"      Sonoda K, Ikeda S, Mizuta Y, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004; 39:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/41\">",
"      Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/42\">",
"      Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/43\">",
"      Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/44\">",
"      Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/45\">",
"      Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/46\">",
"      Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/47\">",
"      Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/48\">",
"      Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996; 91:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Foucher P, Camus P. Pneumotox online: the drug-induced lung diseases. www.pneumotox.com (Accessed on April 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/50\">",
"      Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992; 101:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/51\">",
"      Salerno SM, Ormseth EJ, Roth BJ, et al. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/52\">",
"      Jain N, Petruff C, Bandyopadhyay T. Mesalamine lung toxicity. Conn Med 2010; 74:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/53\">",
"      Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis 2010; 4:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/54\">",
"      Brechmann T, Heyer C, Schmiegel W. [Methotrexate-induced pneumonitis in a woman with Crohn's disease]. Dtsch Med Wochenschr 2007; 132:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/55\">",
"      Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/56\">",
"      Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/57\">",
"      Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/58\">",
"      Weatherhead M, Masson S, Bourke SJ, et al. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006; 12:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/59\">",
"      Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/60\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Mu&ntilde;oz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/61\">",
"      Heraganahally SS, Au V, Kondru S, et al. Pulmonary toxicity associated with infliximab therapy for ulcerative colitis. Intern Med J 2009; 39:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/22/29034/abstract/62\">",
"      Veerappan SG, O'Morain CA. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009; 21:830.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4344 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29034=[""].join("\n");
var outline_f28_22_29034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16433788\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16435177\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112987388\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5621233\">",
"      PRIMARY RESPIRATORY INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112987945\">",
"      Airway involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary parenchymal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987815\">",
"      - Abnormalities in pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987822\">",
"      - Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987829\">",
"      - Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987836\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987843\">",
"      - Pulmonary infiltrates with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112987850\">",
"      - Necrobiotic nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DRUG-INDUCED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      5-aminosalicylic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Azathioprine and 6-mercaptopurine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16433751\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5620986\">",
"      Airway involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5620994\">",
"      Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5621002\">",
"      Serositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5621010\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5621018\">",
"      Drug-induced interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8794801\">",
"      Airway involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8794843\">",
"      Pulmonary parenchymal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94183192\">",
"      Serositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8794815\">",
"      Pulmonary thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112987881\">",
"      Drug-induced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272016037\">",
"      PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16433788\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2370939\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2370950\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4344|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/37/597\" title=\"diagnostic image 1\">",
"      Inflammatory bowel disease CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4344|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 1\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4344|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/50/32545\" title=\"picture 1\">",
"      Necrobiotic nodule Low",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4344|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/32/28173\" title=\"table 1\">",
"      Extraintestinal manifest IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/31/9724\" title=\"table 2\">",
"      Lung disease in IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/51/33595\" title=\"table 3\">",
"      Hypercoagulability in IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=related_link\">",
"      Operative management of Crohn's disease of the small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_22_29035="Chronic inotropic agents HF";
var content_f28_22_29035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chronic inotropic agents in heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Digitalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin and others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phosphodiesterase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milrinone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enoximone*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Calcium-sensitizing agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pimobendan*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levosimendan*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phosphodiesterase inhibitors with sodium and potassium channel modulating effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vesnarinone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Beta-receptor agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dopamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dobutamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xamoterol",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Growth hormone (somatropin)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not approved by US FDA.&nbsp; Available in many countries outside of US.&nbsp;",
"     <br>",
"      &bull; Not approved by US FDA and limited or no availability outside US.",
"      <br>",
"       &Delta; Not approved for management of heart failure by FDA.",
"       <br>",
"        &nbsp;",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29035=[""].join("\n");
var outline_f28_22_29035=null;
var title_f28_22_29036="Causes of APVL";
var content_f28_22_29036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acute persistent visual loss - Anatomic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Media problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Infectious or non-infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Corneal edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Acute glaucoma (primarily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hyphema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Spontaneous or traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alterations in crystalline lens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Thickening, clouding or dislocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vitreous hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Spontaneous or traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Retina problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinal vascular occlusion (CRAO, CRVO)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinal detachment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute maculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Problems of the neural visual pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Optic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Ischemia, inflammatory, or infectious process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Papilledema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Elevated intracranial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chiasmal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Pituitary apoplexy (primarily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Retrochiasmal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Brain lesions in the visual pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma as a cause of any of the above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Acute glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Vision loss due to corneal edema and/or optic nerve ischemia in the setting of severely elevated intraocular pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional visual loss",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRAO: central retinal artery occlusion; CRVO: central retinal vein occlusion.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29036=[""].join("\n");
var outline_f28_22_29036=null;
var title_f28_22_29037="ACEI in diabetic nephropathy";
var content_f28_22_29037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor slows progression of diabetic nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 255px; background-image: url(data:image/gif;base64,R0lGODlhqAH/AOYAAP///4CAgAAAAEBAQMDAwP+AgKCg//8AADAwMHBwcBAQEBAQ//Dw/9DQ0CAgIPDw8LCwsFBQUKCgoODg4AAz//9AQJCQkP/AwP8QEAAA///w8P+goP/Q0GBgYP8gINDQ/1BQ///g4P9wcGBg/7Cw//9QUP+QkDAw//8wMP9gYP+wsEBm/yAg/8DN/+Dg/8DA/0BA/4CA/4CZ/3Bw/5CQ/xBA/9DZ/6Cz/2CA/1Bz/3CN/zBZ/yBN//Dz/7DA/5Cm/38AAODm/4AwMN9ggDAg7oBAQH8gn1BAbz8APz8Av28ADwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACoAf8AAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP0qRMWARKD9wEQ9f8AdTVQoACBgAEAJhA0mCCgw4ewAghoKEAAgAQCLABQIOABxI8gTQ0UEEGAvgECCABAqXIQgQAwY7YMSbPmowkIHHDssDJlz5kAXsYMMCCAzaNIEZUk8MBBypL+DDZQBDOpVasdBHSAwHGCBJIQBDhYVPWq2ZoPSgpA4O8iRwRT/6kaPUu3rly7ePMKKqu3r1m+fuu2GNxi0AodlGysuJEOcOCzFCJTqGEDAIUVlFpQkNF47mO6kQH8oJDDMuYgOFYc7iHoRo7VPWSsyOEDgGYdqWsDsJFaB2tvjj9bDa0Z82XbK2TgoIADgAzSMni02FFDxg4KNjTzsI49SI0dMr5/Cy78HwMDLxRF5s74OIAbqY/X4CGoR3HlmzVz9rF5dG0d2AHnWXn1nAdCBiCkl0hkqjFmGgAA6lDcg4LcJ4MMg21m22bPFdZhLAnoAwA+p5BHoDskHHgCDQwwEhohx61AgQ83HJcDBT+0kEMLNdRwQws//MjcdNjZQFoLPNQAy/8DBCDQAQEERICQKSaemA4JIyywoguPvDjIcTbUcNlxPeAgJg9B2HAjBTz4oJmYPrbGAwU7VPYKARXlqVWJA1p5ZZZbsjNBAA4UFYAFHlHZp5/kfDDDAizM8EE8DUywSpWMcuMoC5FOOk8DUg4wQEOKZhrOpgtICpBTeU5ZCqamTuMCDScsMAIJD5F06aKxykqrrbh+FAGpqcDaqzIM0IpgsCF1oICoo5IiVFHHSmPAgSAY0KJNKLUqLUzUVtsMAzFoqa24kRiLri8fjICgglc1YBABDmhU6rrGkABDqlzShQBBBCTgKinq4mtLspyyiJcAEAzw0sCjFGywLC48CgP/s3gpYMEAEDjA070T7/LCgSN42pdEeQIVMa8hz2JArTFs+9jGEbQFcsuzkGsugRAYNWhcr7KM8yrtvmulA3MNEAGfQ8OiL7+M+gQAUUw3vQrCLCicqccPPOBk1VafUvECFx+LckUqiyJx2JeMnEHJ6EqgtM1Bsz0KCTDLXK0EIhYrtN2XuAADCwZMLOWugHdCbgYz6L2uBA5ASQDQBP+deCQksACDyRN3WxHEalt+eSMugLBA4UNLMFTflY9uSbmNh93zz5HwIyI/dCOytuuDvKA550Nj9NTHjnz17NIKFTQRWaLzTkjpC9AAuAIdIPDwTWIlelFGG3V0l/ONlDuC/+NWp+RwB6AnYsFaHGnE0k+ECBVTuOAn8sIJJ8AL+AA5lWRvIxLZSlfe9z6XDIUozRsdA7IkPdeNZC3aY8T6jMISqABAKt+rXyFoYCvyXW5ytRMLVxTwgK/UTCzM0yAh7scC/bnuAQKrWSQgJ5a4JOAtlDvE7oa2wAXEQIWeYxjYwGeABYCgXxoUgFG8lj5Q7HBiHxicC+snw6kt7WaXY8CjfqhCQnSgUANwQKGIFTreFREGSOyiIIL4ubpdLooswJgaX/HEXi0uZnOcRR1NZQDNpTGPEUmguD5wOkDWYo9+IiTqDKlHQfZKkYxcBAGeNMSWQTKSimjA53LoREdmiv8BLBgBJhvxEtaFApHCYcAJRDnKQ4gKcS1TJStbaQiqqQKVgZElLRGBEWiRcWUtg8EJdomIIDbxE7jsywhO4EFitiKZeVlmM4kZAQQkRAGenMS0svkZaToTEUK8yDE3sU18PWqazgynwCrZqyIC75uEiIACEoCR/7VOXO6EZyIawCoERBCY1cqnPhUBQlRA8yoGyMA7ByqIhkUgbfeM1SUZWghN5slSBuWmXSZKUUIEQAEQ4IpGK3HQo3C0o4OwJf2weKKTonQvemojS8sDylm+1KMxPQg7U7nKm9qipCDRpU8POVKkCHWotAAqRISJ1J8W1SbebCoimETVnSqTmVL/RcRXUoKAX5ZROFHNqiEckJPrzTQv5xQrOAngsHVGAkqJwh0jlFoPgap1rNX7qFcXsVWVJI8hKQyMXe9aiLBURAEYdYRC0LY9jXDkn4WgqzwGS9iKHiqxjoCWTwgoNUHID1xPdUhCF1pZQTRAcpxUH2I5q5ICevaAK7XLoxZZ2kIIT6aNYGOUhIjBREi2HS7A3x9rOwgBYBMmpswklAyCKBOGZSwZpMsLUkXcRCDNEgW84VpS69HQzqNctK2uSybpMChxF5nehQcDhEna6uZUp2etyXTHJ17dHTAfVqUJeOvL15aENL8fWe8J2ouXEJigABvQgCkqIAIAbKACHFBF/7jc6kaTdrA8GziAhg9QgUdwuBIIBkABDnABVOApplescE1okIHwBiYEB8BAiTlQAAdXoAIlUAEAQlAAFYigAjrOsAcKEAIAmADHOhbxBo5cYyXTWMkiJjEqGjAABYAxAuf1xG/BwQAQsIDA4QjBBgpA5jKb+cxoTrOZS4wIExygwYQogQgK4IEDhOACBxgyCg7AARHEGMJ+FkEJDqDjGAv6ACYAQIw1rOgOj5jNqJAARCMKkg+wAATo/IaPPYCBEqj506A+M6QNMeImD4LHFajzBfBcYxUcoMYfBgAGUAAADRygBI2u9YcPQGtBfPjR19hyN1jcwHIYeNAoEMGoUf+R4Q4LIgQhmPUGUkBiVgPA2rHOdoe1nWtfO1rK1hC2Nrr8ZXJoQAUp4HQJNlDkV9S5AgUoQQXwXIILVKDaB0jBBfYc4TxfIASDVsGIE83rC1Cb4M7ONbDDnV5xWBrT4uDAkXldgAjPAuAa9kCiqT1rfNcZAxsQxIj5rIFBYwDOMcbAm709iF+D2xQpkTQsRRs9cGhg2pxOQYKJYW0PJ7wWSnQSagH8jh5OERs03nMFTGBxY/TcEbG2BRvhq2J6fOAEMMg0NMScAgx4IAUqUPCJHmCBQsUkuadsODeKyEVsXEAEey4B03tVqZnLw+jYUEEFvC6CJFcrLcbda9qtjnX/rTNDBBgwQbvXhRL+KZHo6CCBD7ERAhSgYPH4Uuc4NVHOeDxKjtO4wMlxhk0ApCXFoei8O4J7guFKowAgD56ecvfVdhRxBtjQQAVQ0HSc0Yz2tV9HQl0sDdGnQOxNFXcyho8N2IdcrMo/BvOtoXve3zX6xZh+NTiAgeMTFvvD0D413Px8wKluKFnmBPiDIX5plNwDvbfb1CfdifX/ov3R4IAHSoD8xA3AAlAyKg6AeoNnDvgHDW6WaLwTTgi0eZpgf7xwgM7wfvF3OToRADcUAbYEUOMggc2gf/xXP1xxWA2QAPZUgOLggcywAYnXRUxCf53UgS1GDRrQdcvmPKDi/0uQZw0qqAwcgAIV0H/1wyq4RWnd0IPJwIKm1kW6cktqRwxIeAw1KGOANCx2tw1RaAw/GISG5Cw6+AgNgFz7gA/AF1lPyH4zKA0qgAFLmEfGBAl60hB/tTzRlQ1ZWAyI53dIpQ8W1VjdA1ndtXZpuHWWh3l5xBSnNXQhNBasFT+wdYa9cIfCIGajh0nmoycOaAgW1IgGNBSxVQ2S+AubhgFA1koB4BWrAwkPgBIiYkG9ZV92OIjJcGy8pmylhRMHARNeARYoVIfTEIq4cG7p1mnsBk/QcoyCdwgnljJusV2BBYqyOAwSd28oUHEU9V6Z+ICQeAvAKAs3N4w6J4T8df8JEKgK3fgKScdhc9dUMDQ3GUUN57gKXOd1YCeOQxVEZYhevxiNuPB2cbeOhPV4TLSD2cePtbABJcB3elhaHLMX2ZgJ5VgK8UgKPDZrildfopITojKABCkMEykKBpdvN0hc2NiRwPCRn3BzHjBk9jiOV4gMXVZItBACiFcB5eeShCAwX1h1xyB5EDcLFzBoKVCBOLlGmGiSuhCToNcKGmACK2kCLVmUheAA+ahl25gKPml4pRACXVeKUukICPCQmBCRmqCUsqB33WeIX3kIOmkQBBh8wpCVsNCUTxmVa0kInuMA6ad+VzkKZomO1FZvd8kLZFkJcukKD3ZyajmYixD/hhaAWUbIC3/JChpAZx6wc4wJCVtlXHu5CYWJOUaklZ8QkvqWmZOgAA8FAQjwlp6gerswmalwcyjAhotpmo0gNRuYeqDVC4eJCjc3aOtmm5aQExg4T0ipCrBpCiqAbFApnJfwQP50nKjQm6WAbhZZm86pTZ3Jl7iQnKJgnShwkdmpCXJTFICIgrRAnaHQZ3xHlONZCVmRJ9EZX6zgnZ7QZyspAu75npWgSTXzEtxDn6qgnp2Anye3n/xpCYTiRWJJjn0JCfapCQY2m2CXoKc0MLnJga5AoJkwod23kBaqZTnVoAr6oIwQoZbQlHEHoiGKTCMqnWVZRD+pCRdgAsCJ/5ktOg0Q+AKAspSSwAEb8GN5Fo45Gmwm+jwxwCkx4HqPcG4FsHedVgAXYJdFCg3Kdx77MgJH5wgXEG/v1nfYWaXVIGw8SjbnEglAmgJ7hgI6h6Biig2S5QJJygJLCgkh4GP3tn9S+qbmAFRYaitbagga0KUJSYo9RqV8KiCbUKYwcKaJcGcFkG4cJgIb4KaJKg64JKdKyqQXIHAlsGekKAImMJKXmg0985gANFJ/qqWEMKgm8GN1BoQINqWlOg4Y8S+INVfcxKjawgEClwL3xmEp0GOWWqvc8ADGNSJ06IuKIKdEkARGMAS7l2cMNqqIaqzhgCcIoa2G8FlEYSj3Ff+uR4AESgAE5goEQlAE4bqu7Nqu7vqu8Bqv8jqv9Fqv9nqv+Jqv+vquMFgO3MqtheCtorKv9zWwBAtb4Hqw36qw85OwCmuwDAuxEeuwBCuxD3ukyqBJ1hQWrGmGVqmP9XeGdKVUIyuykPiZwOAUEFASaOexIQuy3PmyHyuzNOuZJ4uxGWsQxqmrM1uz2tizMRu0QvuzQBsSJHuzRQuRSOuzRDu0TUsTRwuzNpu0Sku1Y2myUhsSUNKa/UoJW9sJX8sJYSu2XSsJY0tOZftWaau22Nq2bvu2cGsNJZQP51kJc5teBZUQ+IAolpC3c8u3lMAPgGtaBACZYIgPEpAoc5v/uP2JuNpzt5ZwWhgluHXbCJIrCH9buY9hEChhTZswEmGECWFIdZ7juZIwulPiNQdhXJqbCKU7CCOhUUd5QatrupIwu6ALXZMQu0ZZEbYbCbyruihBQozCsQBgQZrgFNvJCN3iKhDQNU6xtngpU3hiTa4VCc/bFFJjEI83CfowARUBAMaLvJLwveELAMp7Cdw7F9kbvZSwvkGxFvDjJxJhFPWrCZokRk14CQBLCE5huI4AsKqbE8RTCf87NfPUvdqEEfb7ePfrtQwMAPnrFB07VwncJwcsCXolkAZBwJlyvw+MCdXbJCYhwlQnCOuTjIwgwM7iFPNJCSkswQwTwuWL/xINAcIKXMPLM8IG0bKZNMM5HMOnC8RL1MIQxCgxXE/4q1M07LUnjBEFbLbwNUHHm8ORAMUwpSdFxRJJHKCVwBKahBBNDEAxNRdYPAlnUxGH8nglgbPzAL6Rk8GZoLLz8pzrYz0eURJIEwDSC7t3zBRfYT09TAl6DBOFCyVZ0QEALEkIgIEVMQFwTC8CsMiM7MiTjL4MU8e1g8haYSmFzMeSMAGcrMiBTMI+/Bg05ACnfLo6u8q5pScqUcaTEEQqoV3XRQmyDFPchIsiJAip7MqIwMtUaVqtrKDdm8to3L227MZx28zO/MzQHM3SPM3UXM3WfM3YnM3avM3c3M3eXOIKcEW4lJxJAwDM39wNFaER4GvFVOETeMLM5wwMFTEWwjMXv7cXErAxHfAAE4ASHSBpEyEwc9EA6BMB5hzP0CAWDGNlj4cRCWBBvusUHcBPa5EAJ1ZlJgG+jdwBFYzQ1HAQ8oRNj1cQpqcrOoWsYuzOjxcWAZC/Jti6Hp3QHDMR9wtfOmXTKa0S7xy/RtEwbxHT26BTTHG/UCERGoHTU6NEUPJ47zxJEEAABAHU2kB19wt4O4vUE0DBO/3OvAwXUv3VYB3WYj3WZF3WZn3WaJ3War3WbN3Wbv3WcB3Xcj3XLRoIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of the administration of placebo or captopril to patients with type 1 diabetes with overt proteinuria and a plasma creatinine concentration equal to or greater than 1.5 mg/dL (132 &micro;mol/L). The likelihood of a doubling of the plasma creatinine concentration (Pcr) was reduced by more than 50 percent in the captopril group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lewis EJ, Hunsicker LG, Bain RP,&nbsp;et al.&nbsp;N Engl J Med 1993; 329:1456.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29037=[""].join("\n");
var outline_f28_22_29037=null;
var title_f28_22_29038="Nasal septal deformity";
var content_f28_22_29038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial computed tomography of congenital nasal septal deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29038=[""].join("\n");
var outline_f28_22_29038=null;
var title_f28_22_29039="Gram stain pleural 1 answer";
var content_f28_22_29039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacteroides fragilis in pleural fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of purulent pleural fluid (x1000) shows inflammatory cells and thin, hard-to-see, gram-negative bacilli. The obligate anaerobe Bacteroides fragilis grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_22_29039=[""].join("\n");
var outline_f28_22_29039=null;
